Protease activity as a prognostic factor for wound healing in venous leg ulcers. by Westby, MJ et al.
Cochrane
Library
 
Cochrane Database of Systematic Reviews
  Protease activity as a prognostic factor for wound healing in venous
leg ulcers (Review)
 
  Westby MJ, Dumville JC, Stubbs N, Norman G, Wong JKF, Cullum N, Riley RD  
  Westby MJ, Dumville JC, Stubbs N, Norman G, Wong JKF, Cullum N, Riley RD. 
Protease activity as a prognostic factor for wound healing in venous leg ulcers. 
Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012841. 
DOI: 10.1002/14651858.CD012841.pub2.
 
  www.cochranelibrary.com  
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review) 
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
BACKGROUND.............................................................................................................................................................................................. 4
OBJECTIVES.................................................................................................................................................................................................. 6
METHODS..................................................................................................................................................................................................... 6
Figure 1.................................................................................................................................................................................................. 9
RESULTS........................................................................................................................................................................................................ 12
Figure 2.................................................................................................................................................................................................. 15
Figure 3.................................................................................................................................................................................................. 16
Figure 4.................................................................................................................................................................................................. 18
Figure 5.................................................................................................................................................................................................. 19
Figure 6.................................................................................................................................................................................................. 20
Figure 7.................................................................................................................................................................................................. 20
DISCUSSION.................................................................................................................................................................................................. 21
AUTHORS' CONCLUSIONS........................................................................................................................................................................... 22
ACKNOWLEDGEMENTS................................................................................................................................................................................ 22
REFERENCES................................................................................................................................................................................................ 23
CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 35
DATA AND ANALYSES.................................................................................................................................................................................... 58
Analysis 1.1. Comparison 1 Protease activity continuous, Outcome 1 t-test assocation of protease level and healing
(dichotomous).......................................................................................................................................................................................
59
Analysis 1.2. Comparison 1 Protease activity continuous, Outcome 2 t-test association of protease level and healing: high (≥ 1
cm2/week) vs low (< 1 cm2/week) healing..........................................................................................................................................
60
Analysis 1.3. Comparison 1 Protease activity continuous, Outcome 3 Correlation coeGicients: protease levels and change in
size..........................................................................................................................................................................................................
60
Analysis 2.1. Comparison 2 Protease activity dichotomous, Outcome 1 Association of healing with elevated protease level; by
protease modulating (PM) intervention..............................................................................................................................................
61
APPENDICES................................................................................................................................................................................................. 62
Figure 8.................................................................................................................................................................................................. 71
Figure 9.................................................................................................................................................................................................. 72
Figure 10................................................................................................................................................................................................ 73
Figure 11................................................................................................................................................................................................ 74
Figure 12................................................................................................................................................................................................ 75
Figure 13................................................................................................................................................................................................ 76
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 78
DECLARATIONS OF INTEREST..................................................................................................................................................................... 78
SOURCES OF SUPPORT............................................................................................................................................................................... 79
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 79
INDEX TERMS............................................................................................................................................................................................... 79
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
[Prognosis Review]
Protease activity as a prognostic factor for wound healing in venous leg
ulcers
Maggie J Westby1, Jo C Dumville1, Nikki Stubbs2, Gill Norman1, Jason KF Wong3, Nicky Cullum1, Richard D Riley4
1Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of
Manchester, Manchester Academic Health Science Centre, Manchester, UK. 2Leeds Community Healthcare NHS Trust, St Mary's Hospital,
Leeds, UK. 3Manchester Centre for Plastic Surgery and Burns, Wythenshawe Hospital, Manchester University NHS Foundation Trust,
Manchester, UK. 4Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK
Contact address: Maggie J Westby, Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology,
Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Jean McFarlane Building, Oxford Road,
Manchester, M13 9PL, UK. maggie.westby@manchester.ac.uk.
Editorial group: Cochrane Wounds Group
Publication status and date: New, published in Issue 9, 2018.
Citation: Westby MJ, Dumville JC, Stubbs N, Norman G, Wong JKF, Cullum N, Riley RD. Protease activity as a prognostic factor
for wound healing in venous leg ulcers. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012841. DOI:
10.1002/14651858.CD012841.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Venous leg ulcers (VLUs) are a common type of complex wound that have a negative impact on people's lives and incur high costs for
health services and society. It has been suggested that prolonged high levels of protease activity in the later stages of the healing of chronic
wounds may be associated with delayed healing. Protease modulating treatments have been developed which seek to modulate protease
activity and thereby promote healing in chronic wounds.
Objectives
To determine whether protease activity is an independent prognostic factor for the healing of venous leg ulcers.
Search methods
In February 2018, we searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid
Embase and CINAHL.
Selection criteria
We included prospective and retrospective longitudinal studies with any follow-up period that recruited people with VLUs and investigated
whether protease activity in wound fluid was associated with future healing of VLUs. We included randomised controlled trials (RCTs)
analysed as cohort studies, provided interventions were taken into account in the analysis, and case-control studies if there were
no available cohort studies. We also included prediction model studies provided they reported separately associations of individual
prognostic factors (protease activity) with healing. Studies of any type of protease or combination of proteases were eligible, including
proteases from bacteria, and the prognostic factor could be examined as a continuous or categorical variable; any cut-oG point was
permitted. The primary outcomes were time to healing (survival analysis) and the proportion of people with ulcers completely healed;
the secondary outcome was change in ulcer size/rate of wound closure. We extracted unadjusted (simple) and adjusted (multivariable)
associations between the prognostic factor and healing.
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Data collection and analysis
Two review authors independently assessed studies for inclusion at each stage, and undertook data extraction, assessment of risk of bias
and GRADE assessment. We collected association statistics where available. No study reported adjusted analyses: instead we collected
unadjusted results or calculated association measures from raw data. We calculated risk ratios when both outcome and prognostic factor
were dichotomous variables. When the prognostic factor was reported as continuous data and healing outcomes were dichotomous, we
either performed regression analysis or analysed the impact of healing on protease levels, analysing as the standardised mean diGerence.
When both prognostic factor and outcome were continuous data, we reported correlation coeGicients or calculated them from individual
participant data.
We displayed all results on forest plots to give an overall visual representation. We planned to conduct meta-analyses where this was
appropriate, otherwise we summarised narratively.
Main results
We included 19 studies comprising 21 cohorts involving 646 participants. Only 11 studies (13 cohorts, 522 participants) had data available
for analysis. Of these, five were prospective cohort studies, four were RCTs and two had a type of case-control design. Follow-up time
ranged from four to 36 weeks. Studies covered 10 diGerent matrix metalloproteases (MMPs) and two serine proteases (human neutrophil
elastase and urokinase-type plasminogen activators). Two studies recorded complete healing as an outcome; other studies recorded
partial healing measures. There was clinical and methodological heterogeneity across studies; for example, in the definition of healing,
the type of protease and its measurement, the distribution of active and bound protease species, the types of treatment and the reporting
of results. Therefore, meta-analysis was not performed. No study had conducted multivariable analyses and all included evidence was of
very low certainty because of the lack of adjustment for confounders, the high risk of bias for all studies except one, imprecision around
the measures of association and inconsistency in the direction of association. Collectively the research indicated complete uncertainty as
to the association between protease activity and VLU healing.
Authors' conclusions
This review identified very low validity evidence regarding any association between protease activity and VLU healing and there is complete
uncertainty regarding the relationship. The review oGers information for both future research and systematic review methodology.
P L A I N   L A N G U A G E   S U M M A R Y
Protease activity and its association with future healing of venous leg ulcers
What is the aim of this review?
The aim of this Cochrane Review was to find out if there is a link between diGerent levels of protease in venous leg ulcers (open skin wounds
on the lower leg caused by problems with the way blood flows through the veins) now and the healing of wounds at some time in the future.
Protease is an enzyme, a chemical naturally produced by the body that breaks down proteins and which may aGect wound healing. We
wanted to know whether having higher protease levels meant that wounds were less likely to heal or to heal more slowly. If so, this could
help find the most useful treatments for each person with a leg ulcer. Review authors from Cochrane collected and analysed all relevant
studies to answer this question and found 19 studies.
Key messages
At the moment, there is complete uncertainty about any association between protease activity and venous leg ulcer healing, but this review
did give pointers on what may be important for future research on natural chemicals present in wounds and their eGect on healing.
What was studied in the review?
Venous leg ulcers can last weeks, months or years. Leg ulcers can be painful, may become infected, and may aGect mobility and quality of
life. The usual treatment for venous leg ulcers is compression therapy (e.g. compression (elastic) bandages), but even this does not work
for everyone (about a third of people still have wounds that have not healed aOer six months). We wanted to find out why these wounds
oOen do not heal, and whether there are factors in the wound (called biomarkers) that can indicate which wounds are unlikely to heal. It
has been suggested that wounds are slow to heal when there are high levels of protease. In this review, we investigated whether there was
any evidence that higher protease levels at the start of a study were associated with slower healing leg ulcers or less healing at a future
time point (such as six months).
In February 2018, we searched for relevant studies that had a reliable design and that investigated links between protease levels and future
healing of venous leg ulcers. We found 19 studies involving 646 people. Not all studies reported the age and sex of participants. In those
that did, the average age of the participants varied from 51 to 75 years. Eleven studies gave results we could use, involving 13 groups of
people. Most people had wounds that had been there for at least three months.
What were the main results of the review?
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There were many diGerences among the included studies: for example, how they defined healing, the type of proteases and how they
measured them, the types of treatment and how they reported results. This lack of consistency meant we could not combine and compare
the results, so we summarised the findings in a general way.
A bigger problem was that none of the studies had analysed the data appropriately as they did not take into account the impact of age
or infection or treatments, and so we could not be sure that it was the protease levels that were important for healing, rather than age or
other factors. Most studies were small and could have been better conducted, so it was diGicult to be sure how meaningful the results were.
Overall, the certainty of the evidence was very low. Further studies are needed to explore the importance of biomarkers for wound healing.
How up to date is this review?
We searched for studies that had been published up to February 2018.
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B A C K G R O U N D
Description of the condition
Venous leg ulcers (VLUs) are open skin ulcers (wounds) on the
lower leg (from below the ankle up to mid-calf), that can last
weeks, months or years, and are a consequence of problems in
either the superficial or deep veins (or both) of the legs. Damage
to the valves or vein blockages results in malfunctioning of the
venous system, reducing the eGicient return of blood to the
heart and increasing the pressure in the leg veins (Ghauri 2010;
Vlajinac 2014), which, if prolonged, may result in VLUs. The precise
chain of events that links the high venous pressures with skin
breakdown and a chronic wound is not fully understood (Coleridge
Smith 1988; Valencia 2001). Leg ulcers are frequently associated
with venous disease in combination with vascular disease, which
impairs arterial blood supply, and such ulcers are said to have a
'mixed aetiology' (Marston 2011).
Accurate current estimates of leg ulcer prevalence are diGicult
to identify because most surveys do not diGerentiate between
causes of leg ulceration, or do so per limb but not per participant
(MoGatt 2004; Srinivasaiah 2007; Vowden 2009). One 2011 estimate
suggested that venous ulceration has a point prevalence of
0.29 cases per 1000 in the UK, whilst mixed arterial/venous leg
ulceration has a point prevalence of 0.11 per 1000 (Hall 2014). One
systematic review also reported the point prevalence of leg ulcers
in non-UK studies as: 0.39 per 1000 in New Zealand in 2004, 1.4 per
1000 in Portugal in 2005 and 2.4 per 1000 in Sweden in 2008 (Cullum
2016).
Venous disease is a chronic condition characterised by periods
of ulceration (i.e. an open wound) followed by healing and then
recurrence, though published contemporary data are lacking: one
cross-sectional study from the 1980s reported that half of current
or recent ulcers had been open for up to nine months and that 35%
of people with leg ulcers had experienced four or more episodes
(Callam 1987). This picture was supported by a subsequent (1988)
cross-sectional study (Nelzén 1994).
Several prognostic factors have been independently associated
with slower or reduced healing of VLUs, for example, wound
area, duration of ulcer, age, number of wounds, lack of mobility
(especially ankle) and weight (Ashby 2014; Barwell 2000; Barwell
2001; Chaby 2013; Gohel 2005; Harrison 2011; Iglesias 2004; Lantis
2013; Margolis 1999; Margolis 2004; Milic 2009; MoGatt 2010;
Scotton 2014).
The first-line treatment for VLUs is compression therapy in the
form of bandages, stockings or mechanical devices (O'Meara 2012).
This application of external pressure around the lower leg assists
venous return and reduces the pooling of blood in the legs (venous
reflux) (Fletcher 2013; O'Meara 2012). Alongside compression,
dressings are almost always applied to open ulcers (O'Meara 2014).
Other treatments for VLUs include venous surgery (removal of
incompetent superficial veins) (SIGN 2010), and drugs such as
pentoxifylline (Jull 2012).
Leg ulcers are associated with considerable cost to patients and to
healthcare providers.
Two systematic reviews summarised the literature on health-
related quality of life in people with leg ulcers (Herber
2007; Persoon 2004). Both included qualitative and quantitative
evaluations, and reported that presence of leg ulceration was
associated with pain, restriction of work and leisure activities,
impaired mobility, sleep disturbance, reduced psychological well-
being and social isolation. Ulcers can be painful, malodorous,
prone to infection, and may severely aGect people's mobility
and quality of life (Dumville 2009; Herber 2007). In severe cases,
ulceration can lead to limb amputation, though this is more likely in
people who also have arterial insuGiciency (Dumville 2009; Nelzén
2008; Valencia 2001), or even to a type of cancer known as Marjolin's
ulcer (Choa 2015). Research suggested that people with complex
wounds, including people with VLUs, commonly see complete ulcer
healing as the most important outcome to them (Madden 2014).
The financial cost of treating a person with an open VLU in the
UK was estimated at around GBP 1700 per year at 2012 prices:
the largest component of ulcer treatment cost is nursing time
(Ashby 2014). Another evaluation estimated the mean cost of
treating a person with a VLU in Sweden as between EUR 1332
and EUR 2585 (based on costs for material for dressing changes)
and in the UK as between EUR 814 and EUR 1994 (price year
2002), with higher costs associated with larger and more chronic
wounds (Ragnarson Tennvall 2005). Data from one German study,
which estimated total costs including those classified as indirect
or intangible costs, estimated mean annual costs of treating leg
ulcers as EUR 9060 per person (2006 evaluation). This figure
was higher than other estimates because it included non-health
service costs to the person and to society (Augustin 2012). One
Australian cost-eGectiveness study of 905 people estimated the
mean cost per person per week for treatment of a chronic leg
or foot ulcer below the knee for 24 weeks was AUD 53.31 (which
corresponds to AUD 2772 per year); costs included consultations
with healthcare professionals, compression bandaging, other
dressings and treatments, and community care services, such as
Meals-on-Wheels and home help (Graves 2014).
Research has shown that not all VLUs heal, even under trial
conditions: one large study of 453 participants showed that
about 30% of VLUs did not heal following first-line treatment
with compression therapy over 12 months (Ashby 2014). There
is interest in additional treatments that may improve wound
healing, and one dressing option is the use of protease-modulating
dressings, which are suggested to reduce the activity of a group
of enzymes known as proteases. As discussed below, it is thought
that prolonged and elevated activity of proteases may be a feature
of non-healing wounds, such that appropriate use of protease-
modulating dressings could promote healing. However, evidence
for the eGectiveness of these dressings in VLUs is largely unclear
(Westby 2016). Such dressings are a new development in wound
care in that they are intended to be a 'targeted' treatment aimed at
wounds with high protease activity. In this context, protease activity
dictates subsequent treatment, but there is limited evidence
supporting the use of a test-and-treat approach (Norman 2016). In
fact, the prognostic nature of protease levels in relation to wound
healing is unclear and this will be the focus of this Cochrane Review.
Description of the prognostic factor
A prognostic factor is any measure that, among people with
a given health condition, is associated with a future clinical
outcome; for example, in people with a VLU, lower body mass
index (BMI) may be associated with less time to healing. The
prognostic factor for this review was a biomarker, protease activity,
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
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which is sometimes elevated in open wounds. A biomarker is
defined by the National Institutes of Health Biomarkers Definitions
Working Group (1999) as "a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention" (Biomarkers Definitions Working Group
2001). Biomarkers are medical signs, as opposed to medical
symptoms (which are indications of health or illness perceived
by patients themselves) (Strimbu 2010). Biomarkers may predict
health outcomes, but do not necessarily do so. However, there are
still no accepted definitive biomarkers for making assessments of
chronic wounds (Patel 2016; Yager 2007).
One possible biomarker type that has received some attention for
wounds is proteases, which are enzymes that break down proteins
into peptides and amino acids (Sittampalam 2017); in general, the
various wound-related proteases break down diGerent proteins.
The principal proteases involved in the wound healing process are
the matrix metalloproteinases (MMPs) and the serine proteases,
which break down extracellular matrix (ECM) and connective tissue
proteins such as collagen and elastin (Hahm 2011; Ladwig 2002;
McCarty 2013; Nwomeh 1999; Velnar 2009). This protein breakdown
is thought to be important in the early stages of the healing process
because it facilitates movement of inflammatory cells into the
injury site, which aids removal of unwanted material and bacteria.
However, in the later stages of wound healing, protein breakdown
is believed to be undesirable because the proteases damage newly
formed tissue, preventing completion of healing (McCarty 2013;
Velnar 2009).
Proteases are produced by an inflammatory process, which
also inhibits the synthesis of chemicals that inhibit the action
of metalloproteinases (tissue inhibitors of metalloproteinases;
TIMPs). Some studies have measured the ratio of MMPs and TIMPs
as a biomarker (McCarty 2013; Muller 2008), and it may be more
valuable to consider the balance of proteases and their inhibitors
as a biomarker (LöGek 2011; Yager 2007).
MMPs are divided into seven subtypes on the basis of their
substrates and their domain structure (chemical components)
(Lazaro 2016; LöGek 2011; Vihinen 2002): gelatinases (MMP-2
and MMP-9); collagenases (MMP-1, MMP-8, MMP-13); stromelysins
(MMP-3, MMP-10, MMP-11); metalloelastase (MMP-12); matrilysins
(MMP-7, MMP-26); membrane-type MMPs (MMP-14, MMP-15,
MMP-16, MMP-17, MMP-24, MMP-25); and other MMPs (MMP-19,
MMP-20, MMP-23, MMP-28). The main serine proteases are mast
cell tryptase and chymase, plasmin, human neutrophil elastase
(HNE), cathepsin G, urokinase-type plasminogen activators (uPA)
and tissue-type plasminogen activators (t-PA) (Grøndahl-Hansen
1988). Other protease biomarkers include modular proteins that
combine proteases with other biological species: for example, the
families of A disintegrin and metalloproteinase (ADAMs) (DuGy
2009; Edwards 2008), and A disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTSs) (Kelwick 2015). Chronic
wounds also contain proteases associated with several types of
bacteria (McCarty 2012; McCarty 2013; Percival 2012; Sibbald 2007;
Suleman 2016). The activity level for each protease may be elevated
at diGerent stages of healing and there may also be diGerent levels
of activity in infected wounds (Serra 2016a), but there is currently
insuGicient evidence to diGerentiate proteases according to their
function in the unhealed wound (Amato 2015; Lazaro 2016; RaGetto
2016; Serra 2017).
Protease activity can be measured in wound fluid using
various biochemical tests. Laboratory-based scientific studies
have used several diGerent techniques, including approaches
that primarily detect MMP-2 and MMP-9 (gelatin zymography),
and methods that detect enzyme activity using either chemical
(e.g. quenched fluorescence substrate hydrolysis) or biological
antibody-based methods (enzyme-linked immunosorbent assays
(ELISAs)) (Harding 2011; McCarty 2013; Sittampalam 2017). A range
of methods of obtaining wound fluid has been used and these
vary with the type of protease measured (Cullen 2006; Quirk 2003;
Trengove 1999; Yager 2007). There is also a commercial colorimetric
indicator available, which is said to determine protease activity,
giving a colour change if activity is elevated above a threshold; the
test uses a weighted average of the activity of elastase and one or
more MMPs (Gibson 2014; NICE 2016).
How the prognostic factor may be related to health
outcomes
It has been suggested that, in chronic ulcers generally, non-healing
may be associated with prolonged high activity of proteases in the
wound in the later stages of the wound healing process (Harding
2011; Hart 2002; McCarty 2013; Palolahti 1993).
Proteases are active in all phases of wound healing (haemostasis,
inflammation, proliferation and remodelling) and are therefore
thought to have a number of roles in the normal wound healing
process (Patel 2016; Trengove 1999; Velnar 2009). It is thought that
there is a burst of protease activity at the start of acute wound
healing, and that in normally healing wounds, the activity peaks in
the first few days and then declines to very low levels by one week,
as healing progresses (Harding 2011; Nwomeh 1998).
However, in non-healing wounds, it is thought that high protease
activity may arise through two main routes (involving diGerent
types of proteases): relating to both the host cells (human) and to
bacteria in the wound. It is thought that the two types of protease
activity may reinforce each other (have a synergistic mechanism)
(McCarty 2012; McCarty 2013; Percival 2012; Sibbald 2007; Suleman
2016). In the host, complex inflammatory mechanisms may result
in proteases reaching higher levels and persisting for longer than
in normally healing wounds (McCarty 2013; Trengove 1999). As
previously noted, this persistent breakdown of proteins (proteolytic
activity) is thought to damage newly formed tissue and to degrade
growth factors, leading to non-healing wounds (Cullen 2002a;
Harding 2011; Wlaschek 1997; Yager 1997). Most chronic wounds are
colonised with bacteria, though they are not necessarily infected.
Bacterial proliferation and their formation into film-like material
(biofilms) in non-healing wounds has been linked to chronic
inflammation and then elevated protease levels. Infection refers
to invasion of tissue by bacteria, leading to a clinically evident
pathogenic inflammatory response and tissue damage (Percival
2012; Pugliese 2016; Sibbald 2007; Suleman 2016).
Limited evidence suggests correlations between elevated levels of
MMPs and delayed healing in people with pressure ulcers (Ladwig
2002), or in foot ulcers of people with diabetes (Liu 2009), as well
as in people with VLUs (Mwaura 2006; Serra 2013). It is possible
that association of MMP level with delayed wound healing may be a
general wound phenomenon, however diGerences between wound
types have also been observed (Lazaro 2016; McCarty 2013).
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For VLUs in particular, studies of protease activity in wound
fluid have suggested that there are significantly higher levels of
proteases in ulcer tissue compared with healthy tissue, and that
these levels decrease following compression treatment in wounds
that heal (Beidler 2008); other studies have reported higher levels
in chronic wounds compared with acute wounds (Lazaro 2016;
Trengove 1999; Wysocki 1993).
However, association between protease activity and non-healing
is not clear cut. Limited data from two industry-sponsored studies
found that only 28% of 162 (Serena 2011) and 23% of 139 (Gibson
2013) non-healing wounds of mixed aetiology had high protease
activity; one of these studies reported that 22% of 101 leg ulcers had
elevated protease activity (Gibson 2013).
Wound fluid is a useful source of biomarkers, and its composition
is broadly assumed to reflect the current clinical condition of a
wound (LöGler 2013). Wound fluid can be obtained in a largely non-
invasive way, but to give reproducible and accurate measurement
of biomarkers, the wound fluid has to be collected and processed
reliably. There are several techniques for wound fluid sampling,
including the use of occlusive dressings, entrapment of fluid in
dressings, swabs, other techniques and devices. The duration of
fluid collection can also be important (LöGler 2013).
Importance of evidence about prognostic factors
Biomarkers of this type may potentially be implicated in,
or mediate, particular pathways to non-healing. Studying the
prognosis associated with protease biomarkers has a three-fold
purpose: first, it can help us understand mechanisms related to
healing, including investigating the true causes of non-healing.
Second, it can allow identification of wounds at increased risk
of non-healing, which could allow selective treatment of these
wounds according to the specific biomarker type and level. Third,
biomarkers can be used to monitor a response to therapy (Riley
2013).
Targeted treatment of this type (the 'test-and-treat' or 'stratified
medicine' approach) is important, especially if treatments are
costly or have adverse eGects, so that they are not used where they
will not be eGective (Hingorani 2013). It is likely that there is more
than one pathway to non-healing and other pathways will probably
be represented by other biomarkers. The best approach may be to
determine a set of biomarkers and treat selectively according to
their activity levels.
A commercial test for protease activity is now available (Gibson
2014), and is intended for use at the point of care, in conjunction
with protease-modulating treatments (Barrett 2011; Harding 2011;
Snyder 2011; Snyder 2013). This approach has mainly found
application in diabetic foot ulcers (NICE 2016). A Cochrane Review
on test-and-treat for healing in VLUs did not identify any studies
(Norman 2016).
Why it is important to do this review?
VLUs are a common type of complex wound that have a negative
impact on people's lives and incur high costs for health services and
society. Leg ulcers are painful, sometimes malodorous, prone to
infection and may severely aGect the person's mobility and quality
of life; in severe cases, there is a risk of limb amputation. There are a
number of treatments for VLUs, but many ulcers prove hard to heal.
Two Cochrane Reviews investigated protease-modulating matrix
(PMM) dressings, but there was insuGicient evidence on the
modulation of protease activity. Westby 2016 examined the eGects
of PMM dressings for healing VLUs, and found it was unclear
whether PMM dressings increased the probability of healing at
12 weeks, in comparison with non-PMM dressings (risk ratio
(RR) 1.28, 95% confidence interval (CI) 0.95 to 1.71; 4 trials; 192
participants). The study populations typically comprised people
with diGicult-to-heal wounds, but only one study reported the
level of protease. A second review searched for evidence on
'test-and-treat' approaches for healing VLUs; for example, PMM
treatment given selectively to wounds with elevated protease
activity (Norman 2016). It found no eligible studies. This current
review is the third part of this set of Cochrane Reviews on protease
activity-related treatment.
It is important to investigate whether elevated protease activity is
a prognostic factor for healing. For practical use, the biomarker
should be robust to adjustment for other factors such as age. This
Cochrane Review was mainly exploratory in nature and its focus
was on protease activity in general; it did not address associations
of specific proteases, although we reported the actual proteases
measured.
One literature review summarised clinical evidence on MMPs in
chronic wound healing (Lazaro 2016). The authors reported studies
that found correlations between MMP levels and various measures
of healing, but did not give full quantitative data. They identified
some studies investigating MMP thresholds for healing but these
were in people with diabetic foot ulcers. The review did not examine
the literature on proteases other than MMPs.
O B J E C T I V E S
To determine whether protease activity is an independent
prognostic factor for wound healing in people with venous leg
ulcers.
M E T H O D S
The methods used in this review have two underlying assumptions:
first, that biomarkers are representative of wound processes and
can be used to monitor wound healing. Second, that the removal
of wound fluid does not interfere with the healing processes (Yager
2007). It is unclear how robust these assumptions are.
PICOTS system for this review (population, index,
comparator, outcome(s), timing, setting)
The PICOTS summary for this review was:
 
Population Index (prognos-
tic factor under
study)
Outcomes Timing Setting
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
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People with
venous leg
ulcers
Protease activity Healing:
• time to healing (survival analy-
sis)• proportion of people with ulcers
completely healed
Prognosis:
• any follow-up period for outcome measure-
ment (predicted 8-24 weeks)• prognostic factor measured at baseline,
representing time of wound assessment
Any
 
We used the PICOTS system to formulate the review question,
the objective and the inclusion criteria for the review (Debray
2017; Moons 2014), the comparator was not relevant in our review.
Further details are given below.
Criteria for considering studies for this review
Types of studies
We included reports of prospective and retrospective longitudinal
studies that investigated whether the prognostic factor, protease
activity, was associated with healing of VLUs, as such studies
can produce valid odds or hazard ratios of prognostic factors.
We did not include studies that solely examined the validation
of prediction models, but we did include prediction model
development studies when they also reported associations of
individual prognostic factors (protease activity) with the outcome
under study (healing). We included randomised controlled trials
(RCTs) analysed as cohort studies, provided interventions were
taken into account in the analysis. We included case-control studies
only if there were no relevant eligible cohort studies for specific
proteases. We included case-control studies because the design
can provide valid estimates of associations between a prognostic
factor and outcomes provided that the follow-up time is not too
long. However, we acknowledge that case-control studies oOen
suGer from other deficiencies (Altman 2001): these were assessed
in our risk of bias assessment. We did not include cross-sectional
studies or case reports because the association under study is
inherently longitudinal. We included studies with any follow-up
period, given the prognostic nature of our objective.
We planned to consider evidence separately within the diGerent
phases of prognostic factor investigation: phase 1 (exploratory),
and phase 2 (confirmatory) studies, which provide diGerent levels
of evidence (Hayden 2008; Riley 2013). Exploratory studies identify
associations of many potential prognostic factors and outcomes.
These studies measure associations between single factors and the
outcome ('univariable' or 'univariate' associations), and provide
the least conclusive information regarding the independence of
a variable as a valid prognostic factor. Confirmatory studies aim
to measure the independent eGect of a prognostic factor on the
relevant outcome while controlling for other factors. We planned to
include all eligible studies in the review and, if possible, planned to
restrict the results summary and any meta-analyses to results from
multivariable analyses. Where this was not possible, we included
the results of univariable analyses, taking into account the phase of
investigation in both the risk of bias assessment and GRADE rating
on certainty of the summary estimates.
Targeted population
We included studies of people with a VLU, who were managed in
any care setting and receiving any type of treatment. We expected
the method of diagnosis of venous ulceration to vary, so accepted
definitions as used in the included studies.
We included studies in people with VLUs alongside people with
other types of wounds (e.g. arterial ulcers, pressure ulcers, diabetic
foot ulcers) provided the results for people with venous ulcers were
presented separately, or if most participants (at least 75%) had leg
ulcers of venous aetiology. Where wounds were described only as
leg ulcers without information as to aetiology, we assumed they
were venous in origin because this is the most common type of leg
ulcer.
We included studies that involved participants at any stage in their
treatment pathway, and we recorded, where available, baseline
data on the time since diagnosis and treatments previously
given, together with ongoing treatments. We included studies that
involved participants with any infection status at baseline and
recorded any available data on this.
We excluded studies conducted solely in vitro and animal studies.
Types of prognostic factor
The prognostic factor was protease activity. Any type of protease or
combination of proteases was eligible, either from the host or from
bacteria, including:
• MMPs: gelatinases (MMP-2 and MMP-9); collagenases (MMP-1,
MMP-8 and MMP-13); stromelysins (MMP-3, MMP-10 and
MMP-11); metalloelastase (MMP-12); matrilysins (MMP-7 and
MMP-26); membrane-type MMPs (MMP-14, MMP-15, MMP-16,
MMP-17, MMP-24 and MMP-25); and other MMPs (MMP-19,
MMP-20, MMP-23 and MMP-28);• serine proteases: mast cell tryptases and chymases; human
nucleophil elastase; cathepsin G; plasmin; uPA; t-PA;• proteases combined with other biological species: ADAM;
ADAMTS.
Where possible, we combined these three major categories in the
analyses, taking into consideration cut-oG points used (see 'Data
synthesis' section below).
We planned to include and report separately studies that
investigated as biomarkers the ratio of proteases and their
respective inhibitors (e.g. MMP-2 (protease) and TIMP-2 (inhibitor)).
The prognostic factor could be examined as a continuous or
categorical variable and any cut-oG point was permitted.
We permitted any approach to obtaining samples from wounds,
and any method of measurement of protease activity. We did not
include measures of proteases in the blood or in tissue samples
(biopsies).
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
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We reported all unadjusted (simple) associations between the
prognostic factor and healing and planned to report adjusted
(multivariable) associations between the prognostic factor and
healing, with details on any adjustment factors used, especially
taking into consideration key adjustment factors of age and
infection. No studies conducted multivariable analyses, and for
some studies, we calculated unadjusted associations from raw data
(e.g. mean and standard deviations of protease levels for healed
and non-healed wounds).
Types of outcomes
Primary outcomes
We planned to include the following primary outcomes:
• time to healing (analysed by survival analysis);• proportion of people with ulcers completely healed, at any
follow-up duration.
We planned to consider subgroup analyses to explore the impact
of follow-up time. We accepted study authors' definitions of what
constituted a healed wound.
We recorded study-reported associations and extracted raw
data to calculate univariate associations. Binary outcomes
would preferably have been reported as time-to-event measures
(survival), but failing that, we considered dichotomous summary
data at the longest time point or the key time point specified in the
study's methods section.
Secondary outcomes• Change in size of ulcer/rate of wound closure (e.g. centimetres
squared per day).
If there were no ulcer healing data for a particular association, we
planned to use data on the change (and percentage change) in
ulcer size, with adjustment for baseline size. We did not contact
study authors to request adjusted means when not presented.
Where studies reported change in ulcer size without adjustment for
baseline size, we analysed the results and assigned high risk of bias
to the outcome measurement domain.
For continuous outcomes, we reported either continuous summary
data or dichotomous data with any cut-oG point.
Search methods for identification of studies
We developed a search strategy based only on population terms
and protease terms. We considered adding prognosis filters, but
this review concerned only one type of biomarker and the number
of records identified was manageable without the use of filters.
Therefore, we followed the procedure recommended by Geersing
2012.
We searched the following databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) (2018,
Issue 2);• Ovid MEDLINE (1946 to February 2018);• Ovid Embase (1974 to February 2018);• CINAHL (1982 to February 2018).
The search strategies are in Appendix 1.
In addition, we handsearched the bibliographies of all included
studies and of identified relevant systematic reviews.
Data collection
We collected and analysed data according to methods stated in
the published protocol (Westby 2017), which were based on the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) and guidance from the Cochrane Prognosis Methods Group
(Cochrane Prognosis Methods Group 2018; Riley 2007).
Selection of studies
Two review authors independently assessed the titles and abstracts
of retrieved records against the inclusion criteria. We obtained
all potentially relevant studies in full and two review authors
independently assessed these for eligibility. We resolved any
disagreements at each stage through discussion and, where
appropriate, we consulted a third review author. We did not
contact the study authors to resolve the uncertainty. Where studies
were reported in multiple publications/reports, we obtained all
publications. Whilst we included a study only once in the review,
we extracted data from all reports to ensure we obtained all
available relevant data. We collated multiple reports of the same
study, so that each study rather than each report was the unit of
interest in the review. The study selection process is illustrated in
a PRISMA diagram, see Figure 1. All studies excluded aOer full-text
assessment are listed in a Characteristics of excluded studies table
with their reasons for exclusion.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Data extraction and management
We collected all association data reported between the prognostic
factor and outcomes, with details on any adjustment factors
used. Where necessary, we extracted raw data that would allow
calculation of association measures.
We extracted and recorded data from included studies using an
Excel-based data extraction sheet, which we piloted initially on a
few studies. We based the Items extracted on the CHARMS guidance
(Moons 2014). One review author extracted data, which was then
checked by a second review author. We did not contact the study
authors if key data were missing from reports, because the overall
risk of bias was too high.
We extracted the following data for the prespecified prognostic
factors and outcomes in this review. We collected outcome data as
described in the 'Types of outcome measures' section:
• country and setting in which study was conducted;• study design;• eligibility criteria;• participant details;• ulcer details, including duration of ulcer, ulcer size, number of
ulcers and ulcer history, and ulcer severity (with the system used
to classify this) as reported by the study authors;• treatment details, including compression and debridement
(including type and frequency);• method of obtaining wound fluid for prognostic factor
measurement, including duration of collection;• method of measurement of protease activity (e.g. Gelatin
zymography);• details of each prognostic factor: type of protease/combination
of factors, measurement of prognostic factor (including time
of measurement), type of data (e.g. continuous/any cut-oG
points and if so, whether they were predefined and what the
justification was for that cut-oG point);• details of each outcome: measurement, type of data (e.g.
continuous/any cut-oG points);• duration of follow-up;• type of analysis: explanatory/confirmatory (including the
presence of a predefined protocol and study registration);
logistic regression/Cox regression;• any adjustment factors considered in the analysis;
• association statistics for each prognostic factor for primary and
secondary outcomes (e.g. odds ratios (ORs), hazard ratios (HRs)
and their CIs/variances/standard errors);• loss to follow-up and reasons.
We extracted minimal data where there were no association data
reported.
Assessment of risk of bias in included studies
Two review authors independently appraised the included studies
using a standardised approach. In the case of discrepancies,
the review authors attempted to reach consensus; if necessary,
a third review author resolved any disagreements. The review
authors were not blinded to study authors, institution or journal of
publication because this was not feasible.
We planned to assess risk of bias using an approach based on the
Quality In Prognosis Studies (QUIPS) tool, which is appropriate for
prognostic factor review questions (Hayden 2013; Hayden 2014),
also drawing on ROBINS I tool (ROBINS-I 2017), which assesses the
risk of bias for non-randomised intervention studies (Sterne 2016).
However, because of the absence of multivariable analyses in all
studies. we modified the approach (see below).
Original approach
Our original approach to risk of bias assessment is described fully
in Appendix 2. This approach assesses risk of bias per study for each
prognostic factor–outcome combination, considering six domains:
study participation (selection bias), study attrition, prognostic
factor measurement, outcome measurement, adjustment, and
statistical analysis and reporting. To assess the adjustment bias
domain, we identified key adjustment factors, both from review of
the literature and in discussion with clinicians (Appendix 3).
Each domain is rated as having high, moderate or low risk of
bias. We defined an all-domain risk of bias per study for each
prognostic factor–outcome combination, taking into account all
the above domains, but especially focusing on the key domains of
selection bias, study attrition, adjustment, and statistical analysis
and reporting. As a guide, we assigned risk of bias as follows: low
risk of bias if all (or all key) domains had low risk of bias; moderate
risk of bias if there was high risk of bias for one key domain or
moderate risk of bias for at least two key domains (with the rest as
low risk of bias); high risk of bias if there was high risk of bias for at
least two key domains. We planned to perform sensitivity analysis
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
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considering only studies at low all-domain risk of bias (Hayden
2013).
Post-hoc modified approach
In view of the lack of multivariable analysis in all the studies, we
modified post-hoc the QUIPS risk of bias assessment for domain
6 (statistical analysis and reporting) to avoid 'triple-counting' the
univariate features of the studies which are also addressed in the
GRADE approach and in QUIPS domain 5 (adjustment factors) (see
Appendix 2; Appendix 4). The GRADE approach to prognostic factor
reviews assigns a moderate rating to phase 1 exploratory studies or
other studies reporting univariable associations or having suGicient
data to calculate associations. Domain 5 of QUIPS (adjustment)
assigns high risk of bias if key adjustment factors were not taken
into account in the design or the analysis. We modified the
assessment of risk of bias for domain 6 so that if a well-designed,
appropriately analysed and well-reported exploratory (univariate)
study was described, a low risk of bias was assigned for this domain.
For all other studies, we assigned moderate or high risk of bias
to that domain, taking into account the aim of the study and the
impact of interventions, as well as the other factors in Appendix 2.
Measures of association
We planned to extract all unadjusted and adjusted measures of
association from included studies and to convert eGect sizes, as
necessary, to avoid possible selection bias, thus allowing us to use
data from as many studies as possible.
We had anticipated that results from multivariable analyses would
have been reported as ORs, RRs and HRs and, if so, we would have
used ORs as the common measure of the association, using RRs
and HRs to estimate ORs at a particular time point (Symons 2002).
However, none of the included studies reported adjusted measures
for binary healing outcomes, but some studies provided suGicient
raw data to allow us to calculate associations.
• Where both the healing outcomes and prognostic factors were
reported as dichotomous variables (e.g. elevated and non-
elevated protease activities for complete healing), we formed 2
× 2 tables and analysed these data as the RR.• Where the prognostic factors were reported as continuous
variables and individual participant data (IPD) were given and
the outcome was dichotomous, we conducted a univariate
regression analysis in STATA (STATA 2013).• Where there were summary data, we extracted the mean
and standard deviation protease activity for each healing
outcome state. To obtain an indication of possible associations
between protease activity and healing, we conducted a t-test
to record associations between healing at the follow-up time
(as an independent variable) and protease levels at baseline
(as the dependent variable) (i.e. we investigated the reverse
association).
Where the outcomes were reported as continuous measures (e.g.
change in ulcer size) and the prognostic factor was a dichotomous
variable, we planned to analyse the regression coeGicients with
their standard errors or to conduct a simple t-test. If both outcome
and prognostic factor were continuous variables, we extracted
(or calculated) Pearson correlation coeGicients and P values and
calculated CIs (Lowry 2018).
For consistency, we recalculated associations to be in the same
direction, as necessary, with associations above 1 indicating better
prognosis for positive binary outcomes (e.g. a healed wound). We
did not contact study authors regarding missing or unusable data.
Unit of analysis issues
The prognostic factor (protease activity) and outcome (complete
wound healing) were both considered at the ulcer level. A possible
unit of analysis issue could have arisen when there was more than
one ulcer per person and multivariable analysis was conducted
with adjustment factors measured at the individual level (e.g. age).
This represents clustered data and analyses should be conducted
using hierarchical methods. Where studies included clustered data
of this type, we planned to report this, noting whether data
were analysed correctly, recording this as part of the risk of bias
assessment. We planned to consider including such studies in any
meta-analysis, taking into account the associated risk of bias. No
studies clearly included more than one wound per participant.
Dealing with missing data
We included studies that investigated the relationship between
protease activity and healing regardless of whether there were
missing data and even if limited evidence was provided about the
size of the eGect (e.g. if the factor was mentioned only as being ’non-
significant’ in the analyses). We did not contact study authors to
attempt to retrieve any missing information.
Assessment of heterogeneity
We considered the clinical heterogeneity of included studies based
on the population, measure of the prognostic factor, cut-oG points
used, outcome measurement and methodological heterogeneity
due to study design/potential biases. We planned to synthesise
associations as appropriate within clinically relevant subgroups,
grouping studies regardless of type of protease, duration of ulcer
and presence of infection. We planned to examine the duration of
ulcer and presence of infection in subgroup analyses where there
was heterogeneity.
Assessment of reporting deficiencies
We planned to examine publication bias for each meta-analysis,
provided there were 10 or more studies, by visually examining
asymmetry on funnel plots and testing for asymmetry at the 10%
level, using Egger's test for HRs, and Peters' test for ORs (Debray
2018; Sterne 2011).
Data synthesis
Synthesising data in prognostic factor studies requires us to
recognise the many diGerent ways of reporting and analysing
results, and, where possible, to request alternative data or
to transform results to a common format (see 'Measures of
association' section). We planned to consider the impact of data
transformations using sensitivity analyses.
We had expected that most studies would present data in the
format of dichotomous outcome data and continuous prognostic
factor data (e.g. protease activity), which may have been
dichotomised or categorised using cut-oG values .
AOer carrying out any appropriate transformations, where possible
we grouped together studies with similar prognostic factor cut-
oG points/similar analytical approaches, and represented the data
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
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on forest plots. We had planned to conduct meta-analyses if valid
data were available assessing associations between individual
prognostic factors and an outcome of interest for suGiciently
homogeneous subgroups of studies. We defined 'suGiciently
homogeneous' subgroups according to population, measures of
the prognostic factor and outcome measurement. However, we
considered all data to be at too high a risk of bias to pool. We had
planned to include in the forest plots details of any adjustment
factors considered in the study analyses, but instead gave other
relevant details in the footnotes.
We planned to combine the data for all proteases, regardless
of the source or type of protease mainly because of a lack of
evidence to inform stratification. For prognostic factors analysed
as dichotomous measures, we planned additionally to take cut-
oG points into consideration as described above. We planned to
analyse separately ratios of proteases and their inhibitors.
If meta-analysis had been conducted, we would have analysed HRs
and ORs separately (at similar follow-up points). We also planned
to transform the measures, where possible, so that a single analysis
(OR) could have been conducted. We planned to conduct meta-
regression analysis if there were more than 10 studies providing
suGicient data (Berkey 1995). We planned to conduct meta-
analyses using STATA (StataCorp version 14) with a random-eGects
restricted maximum likelihood (REML) meta-analysis model, which
accounts for any between-study heterogeneity in the prognostic
eGect (Cornell 2014; Riley 2010). Such heterogeneity is common
in prognostic factor studies. Unless the heterogeneity (as assessed
above) was too extensive for appropriate pooling, we planned to
summarise the meta-analysis by the pooled estimate (the average
prognostic factor eGect), the Hartung-Knapp 95% CI, the estimate
of Tau2 (between-study variance) and a 95% prediction interval for
the prognostic eGect in a single population (Riley 2011).
'Summary of findings' table and GRADE assessment
We used an approach modified from the GRADE framework (Guyatt
2011a) to assess the certainty of the summarised evidence for each
prognostic factor–outcome combination (Hayden 2014; Huguet
2013; Iorio 2015). We rated the overall strength of evidence
as high, moderate, low or very low considering the phase of
prognostic study (confirmatory/explanatory or exploratory), the
within-study risk of bias, the directness of evidence, heterogeneity,
precision of eGect estimates and risk of publication bias (Iorio 2015;
Schünemann 2011a). We also considered two 'upgrading' factors,
large eGect and dose eGect, although we noted that high risk of
bias may artificially lead to large eGects (see Appendix 4 for further
details).
We did not present the main results of the review in formal
'Summary of findings' tables because the vast majority of the
evidence was at high risk of bias and this, together with the
study design, meant that the evidence was of very low certainty
throughout. Instead we summarised the findings in the text.
'Summary of findings' tables present key information concerning
the certainty of the evidence, the magnitude of the associations
examined and the sum of the available data (Schünemann 2011b),
and include an overall grading of the evidence. This defines the
certainty of a body of evidence as the extent to which one can be
confident that an estimate of eGect or association is close to the
true quantity of specific interest.
If it was not appropriate to combine results using a meta-analysis
(due to excess clinical heterogeneity), we planned to present the
results qualitatively, considering the strength and consistency of
results using the following schema:
• strong evidence of eGect: consistent findings (defined as greater
than 75% of studies showing the same direction of eGect) in
multiple low risk of bias studies;• moderate evidence of eGect: consistent findings in multiple high
risk of bias or one study with low risk of bias (or both);• limited evidence of eGect: one study available;• conflicting evidence of eGect: inconsistent findings across
studies;• no eGect: no association between participant expectations and
the outcome of interest.
We planned to calculate absolute risk diGerences for the eGect
of the prognostic factor using estimates of baseline risk from the
literature where possible.
Subgroup and sensitivity analyses
We planned to use sensitivity analyses to explore the impact of
study level all-domain risk of bias, first restricting the analysis to
studies rated as having low risk of bias, and if this was not feasible,
to restrict to low or moderate risk of bias.
If there was heterogeneity, we planned to investigate it using the
following prespecified subgroup analyses, provided there were at
least two studies per subgroup:
• baseline duration of ulcer (up to 24 weeks; 24 weeks or greater);
duration may be a proxy for a non-healing wound, in which
protease activity may be associated diGerently with healing;• presence or absence of infection.
We did not plan to conduct subgroup analyses by type of protease
because this would have introduced too high a level of complexity
for this review, but we recorded the type of protease measured.
We planned to consider subgroup or sensitivity analyses to explore
the impact of types of measurement approaches for assessing
prognostic factors.
This Methods section was based on the exemplar Cochrane
prognosis review protocol for prognostic factors (Hayden 2014) and
the general protocol template of the Cochrane Prognosis Methods
Group (Cochrane Prognosis Methods Group 2018). In conducting
the review, we carried out a number of modifications to the
methods, as described above.
R E S U L T S
Description of studies
Results of the search
The search generated 1493 records and one of the review authors
identified an additional paper separately: we obtained 153 full
papers (Figure 1); some of these were reviews ordered for
bibliographic checks and background material; we excluded 110
studies with reasons (Characteristics of excluded studies table). We
included 19 studies described in 21 reports (see 'Included studies'
for explanation). One study was placed in the Characteristics of
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studies awaiting classification section (Cullen 2009); this was a
conference abstract and gave too little information.
Included studies
Studies are described in detail in the Characteristics of included
studies table. In this table, we report two studies twice because they
were RCTs with diGerent risks of bias for each treatment group: we
report each trial arm as a separate cohort (MoGatt 2014a; MoGatt
2014b; Serra 2015a; Serra 2015b).
Nineteen studies (involving 21 cohorts), with 646 participants, met
the inclusion criteria for the review (Ahmad 2015; Cullen 2012;
Frankova 2013; Gohel 2008; Grzela 2014; Harris 1995; HoGman 1999;
James 2003; Litwiniuk 2012; McDaniel 2017; MoGatt 2014a; MoGatt
2014b; Mwaura 2006; RaGetto 2015; Serra 2013; Serra 2015a; Serra
2015b; Smeets 2008; Trengove 1999; Trøstrup 2011; Wysocki 1999).
The size of the cohorts was small, with a median (range) of 30 (7
to 80) participants. Two studies were reported only as conference
abstracts or posters (Cullen 2012; RaGetto 2015).
Most included studies had a cohort study design and two were a
type of case-control study. Eleven studies reported a prospective
longitudinal design (Ahmad 2015; Frankova 2013; Gohel 2008;
HoGman 1999; James 2003; Litwiniuk 2012; Mwaura 2006; Serra
2013; Trengove 1999; Trøstrup 2011; Wysocki 1999), of which
three had 10 or fewer participants (HoGman 1999; James 2003;
Trøstrup 2011). There were six RCTs, two of which reported results
separately for each arm (MoGatt 2014a; MoGatt 2014b; Serra 2015a;
Serra 2015b); two of which reported relevant results for the study
as a whole (Cullen 2012; McDaniel 2017); and two did not give
any useable results (Grzela 2014; Smeets 2008). The remaining
two studies had a type of case-control design nested in a cross-
sectional study (Harris 1995; RaGetto 2015): we have interpreted
these studies as having a longitudinal component that occurred
before the study started.
Eight included studies did not provide suGicient useable results
data in the published report (Frankova 2013; Grzela 2014; James
2003; Litwiniuk 2012; Smeets 2008; Trengove 1999; Trøstrup 2011;
Wysocki 1999). One study reported association statistics only
for an intermediate biomarker for both the prognostic factor
and the outcome (James 2003); the other studies reported both
the prognostic factor and the outcome as continuous variables,
generally giving summary statistics for each, but no association
statistics. To have useable data for the review, we would have
had to request further analyses from the authors. Therefore, we
included these studies for completeness, noted the lack of useable
results and only extracted data for a minimal set of characteristics
(see Characteristics of included studies table). We did not formally
conduct 'Risk of bias' assessments and did not include these
studies in the 'Risk of bias' figures (see 'Risk of bias' section).
The remaining 11 studies involving 13 cohorts are summarised
in this section and analysed in the results section (Ahmad 2015;
Cullen 2012; Gohel 2008; Harris 1995; HoGman 1999; McDaniel 2017;
MoGatt 2014a; MoGatt 2014b; Mwaura 2006; RaGetto 2015; Serra
2013; Serra 2015a; Serra 2015b). There were 522 participants in
these studies, with a median of 40 participants (range 7 to 80).
Six studies were conducted in the UK (Ahmad 2015; Cullen 2012;
Gohel 2008; Harris 1995; HoGman 1999; MoGatt 2014a/MoGatt
2014b); two in Italy (Serra 2013; Serra 2015a/Serra 2015b); one in
the USA (McDaniel 2017); one in Ireland (Mwaura 2006); and one
abstract did not report the country (RaGetto 2015).
Of the longitudinal studies, two had a follow-up time of
substantially less than two months (four weeks: Cullen 2012; five
weeks: Gohel 2008). The other studies ranged from eight weeks
(Mwaura 2006; McDaniel 2017; Serra 2013) to 36 weeks (HoGman
1999); one of these gave correlation coeGicients between protease
levels measured at four weeks and follow-up at eight weeks
(McDaniel 2017).
Participant characteristics
In 10 studies, all the participants had VLUs. In the remaining study,
56% of participants had VLU and 44% had mixed arterial-venous
leg ulcers (MoGatt 2014a/MoGatt 2014b). Three studies had similar
numbers of males and females (Ahmad 2015; Gohel 2008; MoGatt
2014a/MoGatt 2014b); one was about two-thirds male (McDaniel
2017); three studies had about twice as many females as males
(Mwaura 2006; Serra 2013; Serra 2015a/Serra 2015b); and four did
not report on sex (Cullen 2012; Harris 1995; HoGman 1999; RaGetto
2015). Where reported, mean ages ranged from 51 to 75 years. Two
studies reported that wounds were not infected (Gohel 2008; Harris
1995). The mean/median duration of wounds ranged from three
months (Gohel 2008) to 14 years (Harris 1995).
Prognostic factors
The studies investigated the following protease biomarkers; some
studies examined more than one biomarker:
• MMP-1 (RaGetto 2015);• MMP-2 (Gohel 2008; Mwaura 2006; RaGetto 2015);• MMP-3 (RaGetto 2015);• MMP-7 (RaGetto 2015);• MMP-8 (McDaniel 2017; RaGetto 2015);• MMP-9 (Gohel 2008; RaGetto 2015; Serra 2013; Serra 2015a/Serra
2015b);• MMP-10 (RaGetto 2015);• MMP-12 (RaGetto 2015);• MMP-13 (RaGetto 2015);• MMP-unspecified (Harris 1995; MoGatt 2014a/MoGatt 2014b);• HNE (Cullen 2012; HoGman 1999; McDaniel 2017);• uPA (Ahmad 2015).
No study clearly measured bacteria-specific proteases and no
studies reported ratios of biomarkers and their inhibitors.
Studies reported diGerent methods for extracting wound fluid for
analysis of protease activity: occlusive dressings (Ahmad 2015;
Gohel 2008; Harris 1995; McDaniel 2017; Serra 2013); entrapment in
dressings (HoGman 1999; Mwaura 2006; RaGetto 2015), with two of
these studies using dressings already used for treatment (HoGman
1999; Mwaura 2006); swabs (MoGatt 2014a/MoGatt 2014b); and not
stated (Cullen 2012; Serra 2015a/Serra 2015b).
Studies measured protease using ELISA techniques (Ahmad 2015;
McDaniel 2017; Mwaura 2006; RaGetto 2015; Serra 2013; Serra
2015a/Serra 2015b); fluorogenic substrate assay (Cullen 2012);
gelatin zymography (Gohel 2008); and other activity assays (Harris
1995; HoGman 1999; McDaniel 2017; MoGatt 2014a/MoGatt 2014b).
One study reported measurement only of pro-MMP (and this
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was not cleaved to give the active form; Gohel 2008); another
study (Ahmad 2015) measured total uPA including bound and
complexed forms, with the active form level being below the level
of the bioassay; Harris 1995 separately reported total, active and
latent forms of MMP; three studies reported 'activity' (Cullen 2012;
HoGman 1999; MoGatt 2014a/MoGatt 2014b); one study appeared
to measure total MMP (Mwaura 2006); and the other studies
reported concentrations (McDaniel 2017; RaGetto 2015; Serra 2013;
Serra 2015a/Serra 2015b), but it was unclear whether this meant
total MMPs (active and pro-MMP forms).
Two studies used a cut-oG point for the prognostic factor: Cullen
2012 used greater than 25 mU/110 µL for elastase (taken from their
work in diagnostic studies (Serena 2011)) and MoGatt 2014a/MoGatt
2014b used an activity score of 5 or more to define high activity on
a scale of 0 to 10 for MMPs (unspecified). The other studies reported
the prognostic factor as a continuous measure, sometimes in
relation to a standard (Ahmad 2015; Gohel 2008; HoGman 1999), or
per total protein in the sample (McDaniel 2017; Serra 2013; Serra
2015a/Serra 2015b), or as a concentration (Grzela 2014; Mwaura
2006; RaGetto 2015).
This variability in sampling, measurement techniques and use
of standards meant that analyses of continuous outcomes were
conducted using standardised mean diGerences.
Outcome measures
Studies measured healing in several ways: only three studies
reported complete healing as a dichotomous outcome (Ahmad
2015; HoGman 1999; MoGatt 2014a/MoGatt 2014b). Five studies
reported partial healing (other dichotomous measures of 'healing'),
compared with 'no healing,' defined as follows:
• reduction in area of 30% or greater over four weeks versus no
healing (Cullen 2012);• decreased size (greater than 20%), decrease in slough and
development of healthy granulation tissue versus no healing
(Mwaura 2006);• categorical healing: high healing (1 cm2/week or greater); low
healing (less than 1 cm2/week) and no healing (Serra 2013);• granulating wounds versus non-granulating/inflammatory
wounds (Harris 1995; RaGetto 2015).
Two studies compared diGerent degrees of healing:
• high healing (1 cm2/week or greater) versus low healing (less
than 1 cm2/week) (Serra 2013; Serra 2015a/Serra 2015b).
Three studies reported the outcome as a continuous measure:
one measured the change in size (Gohel 2008), and the others the
percentage change in size from baseline (HoGman 1999; McDaniel
2017).
Interventions
Nine studies reported that the participants received compression
therapy (Ahmad 2015; Cullen 2012; Gohel 2008; HoGman 1999;
McDaniel 2017; MoGatt 2014a/MoGatt 2014b; Mwaura 2006; Serra
2013; Serra 2015a/Serra 2015b). Two studies gave no information
on compression interventions (Harris 1995; RaGetto 2015).
In addition to compression, two studies received vein surgery,
as appropriate (Serra 2013; Serra 2015a/Serra 2015b). Six studies
received other treatments, some of which were likely or possible
protease-modulating dressings:
• likely protease modulating: Cullen 2012 (randomised to
collagen/oxidised regenerated cellulose (ORC) matrix with or
without silver);• possible protease modulating: MoGatt 2014a (oxyzyme or
iodozyme plus basic treatment); Serra 2015a (doxycycline);
McDaniel 2017 (oral n-3 eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) plus silver dressing);• unlikely to be protease modulating: Gohel 2008 (non-adherent);
HoGman 1999 (non-adherent, wool padding, etc.); MoGatt
2014b (usual care continued); Serra 2015b ('most appropriate
treatment' - basic treatment).
Excluded studies
We excluded 110 studies from the review for the following main
reasons (see Characteristics of excluded studies table): 13 studies
had an ineligible population (Budzyn-Napierala 2016; Cullen
2002b; Honda 2011; Huttunen 2005; Karatepe 2010; Kucukguven
2013; Mirastschijski 2002; Schultz 2004; Serra 2014; Shields 1994;
Varelias 2002; Varelias 2006; Zamboni 2005); five did not assess
a relevant prognostic factor (Cook 2009; Ibbotson 1994; Senet
2003; Stojadinovic 2014; Wlaschek 1997); 18 did not report an
eligible healing outcome (Bernatchez 2012; Dalton 2005; Eming
2008; Failla 2008; Grinnell 1998; Huttunen 2000; Huttunen 2004;
Impola 2005; Karim 2006; McInnes 2014; Moor 2009; Palolahti 1993;
Rayment 2008; Schmid 1999; Schmidtchen 2000; Wysocki 1993;
Wysocki 1996; Zillmer 2011); 38 studies where the study design
was not longitudinal (Ahmad 2011; Amato 2015; Anon 2008; Ayuk
2016; Bogaczewicz 2004; Bohórquez-Sierra 2006; Clark 2001; Cook
2000; Da Silva 2014; Derbyshire 2003; DuGy 2005; Fisher 1998;
Gordon 1975; Herouy 2000a; Herouy 2000b; Ivins 2014; Körber 2006;
Kucharzewski 2005; Ligi 2016; Lim 2010; McCarty 2012; McCarty
2013; Moore 2007; Nwomeh 1999; Ovington 2001; Phillips 2007;
RaGetto 2014; Rayment 2009; Rogers 1999; Schmidtchen 2003;
Serena 2016; Serra 2015c; Serra 2016a; Singh 2010; Tarlton 1999;
Vahlquist 2000; Weckroth 1996; Widgerow 2011); and 34 studies
where the samples were not obtained from wound fluids or were
not obtained by an eligible method (Alexewicz 2007; Barros 2012;
Caimi 2015; Eming 2006; Fernandez 2008; Gacka 2004; Grinnell
1992; Hasmann 2011; He 1999; Herouy 2004; Herrick 1997; HoGman
1998; Lantis 2011; Lotti 1995; Mirshahi 1995; Nielsen 1992; Norgauer
2002 Pirila 2007; Rechardt 2000; Saarialho-Kere 1998; Salgado 2017;
Serra 2016b; Serra 2017; Stacey 1993; Stacey 2000; Tauzin 2014;
Turio 2002; Ulrich 2005; Vaalamo 1996; Vaalamo 1997; Vaalamo
1999; Van Bergen 1996; Weckroth 2004; Zeegelaar 1997).
One excluded study, Serena 2016, had similarities with two of
the included studies (Harris 1995; RaGetto 2015), in that healing
trajectories were analysed within a cross-sectional study. However,
the trajectories (healing and non-healing) were derived from
measurements of healing rate before the start of the study, rather
than clinical assessment of the phase of the wound in the study.
Therefore, we considered the study to be cross-sectional and
measuring diagnosis rather than prognosis. Additionally, Serena
2016 had only 32% VLUs and it would have been necessary to write
to the authors.
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Studies awaiting classification
We identified one study that is awaiting classification (Cullen 2009).
This was a conference abstract and gave too little information.
Ongoing studies
We found no ongoing studies.
Risk of bias in included studies
No study conducted multivariable analyses, but all 11 studies (13
cohorts) with useable results either had suGicient data to calculate
univariate associations or reported correlations between protease
measurements and a measure of healing. We did not report risk of
bias assessments for studies with non-useable results. However, all
these studies were at high risk of bias due to inadequate analyses
and lack of adjustment.
Figure 2 shows risk of bias judgements for each cohort. Judgements
for each domain across studies are shown in Figure 3. These figures
also included studies that did not have useable results and did not
have risk of bias assessments, and these appear blank.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies with results. Studies without useable results do not have risk of bias assessments, and
these appear blank.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
with results. Studies without useable results do not have risk of bias assessments, and these appear blank.
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Figure 3.   (Continued)
 
Overall, all studies (and all cohorts) except Mwaura 2006 were
at high risk of bias (they had high risk of bias for at least two
domains): this was commonly due to high risk of selection bias
(five of 12 cohorts), outcome measurement bias (nine cohorts) and
adjustment factor bias (11 cohorts). Mwaura 2006 was at moderate
risk of bias overall.
Results
At the outset of this results section, we must stress that no reliable
associations could be identified from the data presented here
because all the evidence in this review was of very low certainty (see
Certainty of the evidence section below). However, as this is a new
type of review in the wounds field, we have presented the full set of
(very low-certainty) results in order to indicate possible factors that
should inform future research and systematic review methodology
in this area. We have not generally reported the numerical findings
in the main text, but these can be seen in the forest plots as
indicated.
Associations of protease activity (continuous data) with
complete healing and partial healing
Healing as dichotomous data (versus no healing)
We used individual participant data (IPD) from one study including
seven participants to conduct a univariate logistic regression
analysis (HoGman 1999). The OR per unit increase in elastase
activity at baseline was 0.96 (95% CI 0.88 to 1.04). This was very low-
certainty evidence.
We used the data from each of six studies including 174 participants
to carry out a 'reverse' t-test of associations between healing and
protease activity (Ahmad 2015; Harris 1995; HoGman 1999; Mwaura
2006; RaGetto 2015; Serra 2013). The (theoretical) interpretation of
this was that a negative SMD indicated that lower baseline levels
of protease were associated with higher proportions of healing
wounds at follow-up (compared with non-healing).
Results from all studies are shown on the same forest plot to visually
display the findings and to allow possible influencing factors to be
considered (Analysis 1.1; Figure 4).
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Figure 4.   Forest plot of comparison: 1 Protease activity continuous, outcome: 1.1 t-test assocation of protease level
and healing (dichotomous).
 
Two studies including 37 participants reported complete healing
(versus no healing) (Ahmad 2015; HoGman 1999). Both studies
investigated serine proteases. This very low-certainty evidence
illustrated inconsistency in the point estimates regarding the
direction of the association, high risk of bias and very wide CIs;
in other words, it is completely unclear whether serine protease
activity is associated with leg ulcer healing. Ahmad 2015 measured
mainly bound and complexed forms of uPA protease and HoGman
1999 appeared to measure the active form of neutrophil elastase.
Four studies including 137 participants reported partial healing
(versus no healing) (Harris 1995; Mwaura 2006; RaGetto 2015;
Serra 2013), with Harris 1995 comparing granulating/epithelialising
('healing') wounds with non-granulating ('non-healing') wounds
in a type of case-control study; Mwaura 2006 reporting a 'healing
wound' as one with more than 20% decrease in wound size,
decrease in slough and development of granulation tissue; and
Serra 2013 comparing 'high healing' (1 cm2/week or greater
decrease in size) and 'low healing' (less than 1 cm2/week) versus
no healing. RaGetto 2015 reported protease levels for wounds
in granulating versus inflammatory phases in a type of case-
control study, with protease levels given for a number of diGerent
proteases.
RaGetto 2015 (a conference abstract) suggested there may be two
types of protease involved in wound healing, which they described
as 'degrading' MMPs and 'reparative' MMPs. We explored this
proposed diGerentiation of proteases in Analysis 1.1 (Figure 4).
The degrading and reparative MMPs in RaGetto 2015 appeared
to have diGerent directions of association with healing, and the
other studies may have supported this interpretation (Harris 1995;
Mwaura 2006; Serra 2013). However, this was very low-certainty
evidence, dominated by a single study which identified healing and
non-healing wounds in the same cohort, and there may well be
confounding and bias (RaGetto 2015).
Healing as dichotomous data ('high healing' versus 'low
healing' chronic wounds)
Two studies including 95 participants examined the association
of protease levels with 'high healing' versus 'low healing' chronic
wounds (Serra 2013; Serra 2015a/Serra 2015b). Both studies
defined 'high healing' wounds as those that had a change in
wound size of 1 cm2/week or greater and 'low healing' wounds as
those that had a change in wound size of less than 1 cm2/week.
Findings are shown on a forest plot (Analysis 1.2; Figure 5). It was
very uncertain whether there was a diGerence in protease activity
between high- and low-healing wounds.
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Figure 5.   Forest plot of comparison: 1 Protease activity continuous, outcome: 1.2 t-test association of protease level
and healing: high (≥ 1 cm2/week) versus low (< 1 cm2/week) healing.
 
Healing as continuous data
Three studies including 122 participants reported (or provided IPD
to allow calculation of) correlation coeGicients between protease
levels and reduction or percentage reduction in ulcer size (i.e.
healing); a positive correlation meant that as protease levels
increased, the reduction in ulcer size increased (i.e. more healing)
(Gohel 2008; HoGman 1999; McDaniel 2017).
Results for all studies were represented on a forest plot, even
though one had no numerical data (Analysis 1.3; Figure 6). Gohel
2008 reported narratively that there was "no relationship" between
the initial levels (of proteases) and subsequent healing at five
weeks (negative, but non-significant correlation coeGicients were
reported for the change in protease levels versus the change in
ulcer size between zero and five weeks, but these were cross-
sectional data only and therefore ineligible). McDaniel 2017,
although measuring protease levels at baseline, only reported
correlations between protease levels at four weeks and the
percentage reduction in ulcer size between baseline and eight
weeks; this study reported results for both arms of the RCT
combined. HoGman 1999 reported IPD for the seven participants
included (four-week protease levels and percentage reduction in
size at 36 weeks). One of these data points appeared to be an outlier
and we calculated the Pearson correlation coeGicient and plotted
a graph both with and without this outlier. This gave very diGerent
correlation coeGicients (albeit with very wide CIs), and was thus an
unstable finding; results from both calculations are shown on the
forest plot. The evidence across all studies was of very low certainty
showing wide CIs, high risk of bias and some inconsistency. Gohel
2008 also reported pro-MMP levels, so was likely to represent
indirect evidence for protease activity and McDaniel 2017 had, in
eGect, a very short follow-up, and combined results for diGerent
intervention arms. It was possible that there was a diGerence in
correlation coeGicients for MMP-8 and HNE in one study (McDaniel
2017), negative for MMP-8 and no correlation for HNE, but the
evidence was very uncertain.
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Figure 6.   Forest plot of comparison: 1 Protease activity continuous, outcome: 1.3 Correlation coeJicients: protease
levels and change in size.
 
Associations of protease activity (dichotomous data) with
healing and partial healing
Two studies (three cohorts) including 164 participants allowed
calculation of an RR for the univariate association of elevated
protease activity with healing: MoGatt 2014a/MoGatt 2014b
reported complete healing at 12 weeks and Cullen 2012 defined
healing as at least 30% reduction in area over four weeks. We did
not pool the data because of the diGerence in healing definition, but
show the results on the forest plot (Analysis 2.1; Figure 7), grouped
according to the interventions: Cullen 2012 gave all participants
an 'established' protease modulating matrix dressing (collagen/
ORC with or without silver); in the intervention arm MoGatt 2014a
participants received oxyzyme/iodozyme treatment, which was
postulated to be protease modulating. In the control group of
MoGatt 2014b the treatment was not protease modulating.
 
Figure 7.   Forest plot of comparison: 2 Protease activity dichotomous, outcome: 2.1 Association of healing with
elevated protease level; by protease modulating (PM) intervention.
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There was a positive association between elevated protease levels
and healing in Cullen 2012 and an indication of a negative
(expected) association in the usual care group of MoGatt 2014b.
Such a trend might be explained by interactions between the
protease-modulating treatment and protease levels. In non-
healing wounds with elevated protease levels, the protease-
modulating treatment may have selectively activated the healing
process by removing excess protease, but in non-healing wounds
with normal protease levels, the causes of non-healing will have
been diGerent and may not have been aGected by protease-
modulating treatments. However, given the very low certainty of
the evidence, there are other biases or confounding factors that
may also explain any trend, including the nature and timing of
action of the diGerent proteases.
Certainty of the evidence (GRADE)
All the evidence was of very low certainty: the exploratory study
design meant the GRADE rating started as moderate-certainty
evidence (Appendix 4), and all studies except Mwaura 2006 were at
overall high risk of bias (high risk of bias for at least two domains)
and so the evidence certainty was downgraded by two more levels,
taking the rating to very low certainty. There was also imprecision in
the findings and some inconsistency. Furthermore, we considered
it likely that in these small observational studies the possible biases
and confounding factors would have a large impact on the results,
so limiting their reliability even more.
D I S C U S S I O N
Summary of findings
It was uncertain whether protease activity was a prognostic factor
for wound healing in people with VLUs because the certainty of
the evidence was very low. Of the 21 cohorts found from extensive
searching, only 13 (522 participants) had data available for analysis.
Of these 13 cohorts, none reported the time-to-healing outcome
and only two recorded the proportion of people with ulcers
completely healed, with other studies recording partial healing
measures (such as 1 cm2/week or greater decrease in size) or
change in ulcer size. There was marked clinical and methodological
heterogeneity across studies, which precluded meta-analysis and
made narrative summary diGicult. This heterogeneity included
diGerences in the definition of healing, the type of protease and
its measurement, the distribution of active and bound protease
species, the types of treatment and the reporting of results. No
study conducted multivariable analysis or provided IPD to allow us
to do so, and all the included evidence was of very low certainty.
This should be interpreted as complete uncertainty of the role of
protease activity in venous ulcer healing rather than evidence of
no association. No reliance can be placed on the validity of the
findings.
However, this review can provide important insights for future
research on the potential prognostic factors in wound healing
generally and of the value of proteases for venous ulcer healing
specifically. We also hope that this review presents an exemplar
for future systematic reviews of biomarkers as prognostic factors in
wound healing and allows reflection on the current clinical context
of protease-modulating dressing use. We enlarge on these aspects
below.
Considerations for further prognosis research
The review was unable to answer the question of whether protease
activity was an independent prognostic factor for the healing
of VLUs. The review highlighted the heterogeneous nature of
protease activity reporting, a lack of standardisation of protease
measurement and a lack of standardisation of how the healing
outcome was defined and measured. Proteases may have a role
in defining the status of a chronic wound, but the limitations
in study reporting mean that it is impossible to draw a robust
conclusion about the role of proteases as biomarkers for leg ulcer
healing. This remains an important question, and there is a need
for well-conducted, further research. Therefore, we propose a
large prognostic factor research study that employs an appropriate
study design and analytical approach, uses advanced methods for
measuring protease activity, and takes account of confounding
factors and treatments in its analysis. The following elements are
important: study design, protease measurement and appropriate
analysis.
Study design
A large prospective cohort study with adequate follow-up times
to measure complete healing as time-to-event is a minimum
requirement for new primary prognosis studies in this field.
Protease measurement
The type of proteases should be selected carefully and advanced
protease activity measurement methods should be used to allow
investigation of specific proteases and focus on the active form of
the enzymes, rather than protease bound to other molecules or
surfaces.
The measurement of proteases has evolved over time and
continues to evolve, and the studies in this review used numerous
techniques ranging from radiolabelled collagen breakdown, to
zymograms, ELISAs, Western blots and fluorogenic substrates.
These tests have now been superseded by more advanced protein
evaluations, which should be used in future research.
It is also important to consider the type of proteases that
would be measured in future research. Proteases have many
diGerent biological functions and activity of one protease does
not necessarily provide a complete wound signature that relates
to the wound phenotype. For example, specific MMPs such as
MMP-2 and MMP-9 have a particular role in type IV and V collagen
proteolysis, but this varies according to the study or clinical
context. In addition, the diGerent temporal and spatial location of
proteases in the wound will depend on which phase of healing
(coagulation, inflammation, proliferation, synthesis, remodelling)
or how inflamed or infected the tissue is, hence the value of
proteases as simple biomarkers may be limited. This would suggest
a whole-system approach to future research, that, as a minimum,
takes into account combinations of proteases and time-dependent
eGects, but preferably also considers demographics, comorbidities,
wound duration, location and bioburden as possible confounding
or interacting factors, which in turn could allow investigation of
mechanisms of wound healing.
Appropriate analysis
A future study should use multivariable analysis of survival data,
with continuous factors analysed on their continuous scale, and
potential non-linear relationships also considered. The study
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should be suGiciently powered to take account of adjusting
factors (Knofczynski 2008). IPD meta-analyses may be needed to
standardise definitions and reduce heterogeneity across studies.
Finally, there may be interactions between protease levels and
protease-modulating treatments, which distort any associations
being studied. Future studies should take interactions into
consideration in the analyses.
Considerations for prognosis reviews in wound care
In the context of systematic reviews of biomarker prognostic
factor studies in wounds, serious consideration should be given to
restricting the reviews to well-conducted studies with multivariable
analyses, and identifying the ensuing evidence gaps separately.
Current clinical context
In the current clinical context, a number of protease-modulating
dressings have been marketed and are used, based on very
limited research that postulates that reducing protease activity
could promote healing and that timing may also be important
(Harding 2011; McCarty 2013). We have shown in this review that
the evidence for protease biomarkers being prognostic for ulcer
healing is of very low certainty. We have also shown in our PMM
intervention review that it is unclear whether PMM dressings are
more eGective than other dressings in healing VLUs (Westby 2016).
There is currently no study evidence on the eGectiveness of a test-
and-treat strategy, in which VLUs with elevated levels of protease
are selectively treated with PMM dressings (Norman 2016).
A U T H O R S '   C O N C L U S I O N S
This review of protease activity as a prognostic factor for wound
healing in VLUs has demonstrated the very low validity of the
evidence, which means that no reliance can be placed on the
findings beyond the conclusion of total uncertainty. The review can
inform future research and give pointers on the methodology of
systematic reviews of biomarkers as prognostic factors for wound
healing. With modern protein assessment tools and validation
using an 'Omics' approach, future complex wound studies should
be able to highlight the significance of many of the proteases in
chronic venous leg ulcers.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Prospective cohort study
Setting: hospital leg ulcer clinic
Country: UK
Duration of follow-up: 6 months
Treatments: compression bandaging (3-layer or 4-layer)
Participants 30 participants with VLUs (recalcitrant ulcers)
Median age (range): 62 (36-79) years vs 70 (40-92) years (healed vs non-healed)
Sex (M:F): 4:5 vs 10:11 (healed vs non-healed)
Stage of ulcer: not reported
Ulcer duration: median (range): 12 (3-84) months vs 19 (2-180) months (healed vs non-healed)
Ulcer size at baseline: median (range): 6 (2-165) cm2 vs 9 (3-140) cm2 (healed vs non-healed)
Wound infection: not reported
Number of wounds: 30 (if bilateral, only 1 limb assessed)
Inclusion criteria: confirmed VLU; incompetence of superficial veins or thrombosed deep veins on du-
plex scan
Exclusion criteria: ABPI < 0.8, immunosuppressed, unable to tolerate compression therapy
Prognostic factors Active uPA (continuous data); total uPA (including receptor bound and complexed to PAI-1 and PAI-2).
Level of active uPA (quote: "below sensitivity of bioimmunoassay"). Measurement method ELISA: total
uPA antigen measurements by ELISA IMUBIND (American Diagnostica). Active uPA measured by bioim-
munoassay with the WHO uPA standard. Activity and antigen measurements normalised against solu-
ble protein concentration (Coomassie Plus protein assay).
Time of measurement: collected before start of compression therapy
Wound fluid sampling method: occlusive dressings (exudate collected from under Opsite (Smith &
Nephew) dressing)
Notes uPA activity measured too, but in all ulcer exudates the level was below the sensitivity of the bioim-
munoassay.
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Moderate: unclear if consecutive participants, but representative; people at a
dedicated ulcer clinic (but inclusion criterion for review was any with VLU).
Attrition bias Low risk No missing data
Ahmad 2015 
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Prognostic factor mea-
surement
High risk Inappropriate biomarker measure: ELISA for total uPA (including bound and
complexed uPA); active bioimmunoassay with uPA WHO standard. Activity be-
low sensitivity level
Outcome measurement Unclear risk Moderate: unclear if blinded; defined as complete re-epithelialisation after 6
months
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting High risk Results reported only for total uPA
Overall risk of bias High risk  
Ahmad 2015  (Continued)
 
 
Methods RCT
Setting: not reported
Country: UK
Duration of follow-up: 4 weeks
Treatments: collagen/ORC/silver treatment and collagen/ORC (randomised); and compression
Participants 64 participants with VLUs
Age: not reported
Sex: not reported
Stage of ulcer: not reported
Ulcer duration: not reported
Ulcer size at baseline: not reported
Wound infection: not reported
Number of wounds: 64 (inferred)
Inclusion criteria: VLUs (no further details)
Exclusion criteria: not reported
Prognostic factors Human neutrophil elastase (dichotomous data); 'elastase activity.' Measurement method fluorogenic
substrate assay: cut-oG point based on Serena 2011 (> 25 mU/110 µL)
Time of measurement: baseline and then every 2 weeks for 4 weeks
Wound fluid sampling method: not stated
Notes Conference abstract. Authors worked for Systagenix and were involved in developing a diagnostic test
based on elevated protease levels.
Risk of bias
Bias Authors' judgement Support for judgement
Cullen 2012 
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Selection bias High risk < 2 months' follow-up (only 4 weeks). Participants from a single clinic implied.
No details
Attrition bias Unclear risk Moderate: 8/64 (12.5%) participants missing due to deviations from protocol.
Unclear whether missing data in people with elevated protease
Prognostic factor mea-
surement
Unclear risk Moderate: cut point validity depended on reliability of Serena 2011 study
Outcome measurement High risk 30% reduction in size. No adjustment for baseline size mentioned
Adjustment factors High risk None of the key confounders taken into account in the design or analysis
Analysis and reporting High risk Likely interaction with treatment that was designed to be protease modulat-
ing. No account in analysis
Overall risk of bias High risk  
Cullen 2012  (Continued)
 
 
Methods Prospective cohort study
Setting: not reported
Country: Czech Republic
Duration of follow-up: 6 weeks
Treatments: gauze hydrogen calcium salts of oxidised cellulose
Participants 20 participants with VLU and other wounds (VLU 15, A-V leg ulcers 3, decubitus ulcer 1, trophic leg ulcer
1)
Median age: 65.7 (SD 7.1) years
Sex (M:F): 10:10
Prognostic factors MMP-2 and MMP-9 (continuous data); total MMP (pro-, active- and TIMP complexed) median (IQR as-
sumed) reported but not linked to outcome. Measurement method sandwich ELISA
Time of measurement: baseline and every 2 weeks
Wound fluid sampling method: entrapment in dressings
Notes Minimal data collection; no results. Risk of bias assessments available on request
Frankova 2013 
 
 
Methods Prospective cohort study
Setting: nurse-led specialist leg ulcer service
Country: UK
Duration of follow-up: 5 weeks
Gohel 2008 
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Treatments: non-adhesive dressings and compression bandaging
Participants 80 participants with VLUs (ABPI ≥ 0.85 open ulceration; chronic ulcers)
Median age (range): 75 (40-93) years
Sex (M:F): 43:37
Stage of ulcer: CEAP grades (level II) C6sEp in 68 and C6sEs in 12
Ulcer duration: chronicity median (range) 3 (1-180) months
Ulcer size at baseline: median (range) 4.7 (0.1-142.4) cm2
Wound infection: 0 participants had signs of soO tissue infection
Number of wounds: 80 (for participants with bilateral areas, largest was studied)
Inclusion criteria: new and follow-up participants with open ulceration between the ankle and knee
and an ABPI ≥ 0.85. Duplex evidence of venous reflux
Exclusion criteria: not stated
Prognostic factors MMP-2 and MMP-9 (continuous data); pro-MMP only. Measurement method gelatin zymography: MMP
concentrations expressed as a percentage of an MMP-2 standard sample used for all assays
Time of measurement: baseline and 5 weeks measured. No results given for correlations with baseline,
but with change from baseline
Wound fluid sampling method: occlusive dressings. Only 34/74 people had wound fluid
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias High risk < 2 months' follow-up (5 weeks). Otherwise representative (consecutive new
and follow-up patients with open ulceration between the ankle and knee and
an ABPI ≥ 0.85 were targeted)
Attrition bias Unclear risk Moderate: assessments were attended by 74/80 (93%) participants; unclear
whether this is likely to affect the results
Prognostic factor mea-
surement
High risk Inappropriate biomarker measure: all assays performed using a sandwich
ELISA technique. Only pro-MMP reported and not cleaved to give an active
form. Wound fluid collection 52/80 (65%) at baseline
Outcome measurement Unclear risk Moderate: unclear if blinded. 'Complete ulcer healing' reported, but only use-
able results were change in ulcer size. No details on assessment
Adjustment factors Unclear risk Moderate: partial, at least half, but not all, key adjustment factors taken into
account in design or analysis (no symptoms of infection in soO tissues)
Analysis and reporting High risk Analysis concerned correlations between changes in ulcer healing and
changes in pro-MMP levels. Baseline MMP levels not reported. Change in size
not adjusted for baseline
Overall risk of bias High risk  
Gohel 2008  (Continued)
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Methods RCT (within person)
Duration of follow-up: 4 weeks
Treatments: Flaminal Forte and hydrocolloid (F) or hydrocolloid alone (H) (1 leg randomised to each),
plus 4-layer compression
Participants 8 participants with VLUs
Mean age: 68.3 (SD 9.3) years
Sex (M:F): 3:5
Number of wounds: 16
Prognostic factors MMP-2 and MMP-9 (continuous data); gelatinolytic activity, due to activated MMPs-2 and -9. Measure-
ment method gelatin/SDS zymography and fluorescent real-time zymography
Time of measurement: baseline, 14 days, 28 days
Notes Minimal data collection, no results. Risk of bias assessments available on request
Grzela 2014 
 
 
Methods Nested case-control design in a cross-sectional study: wounds divided on clinical criteria into those in
granulating/epithelialising and non-granulating phases
Setting: not reported
Country: UK
Duration of follow-up: none, case-control
Treatments: not reported
Participants 18 participants with VLUs (area 8.5-75 cm2; duration, 6 months - 40 years)
Mean age: 73 (SD 12) years (calculated from IPD)
Sex: not reported
Stage of ulcer: not reported
Ulcer duration: mean: 14 (SD 13) years (calculated from IPD)
Ulcer size at baseline: mean: 31 (SD 18) cm2 (calculated from IPD)
Wound infection: none (all confirmed as not clinically infected)
Number of wounds 18 (presumed)
Inclusion criteria: not explicitly stated but VLUs of > 6 months' duration were included
Exclusion criteria: not reported
Prognostic factors MMP (unspecified) (continuous data); collagenases (unspecified); total activity (μg collagen degrad-
ed/hour/mg protein in fluid); also reported separately for latent and active. Measurement method was
3H-labelled type 1 collagen assay: trypsin was added (to cleave latent MMP to active MMP) and the net
total activity measured, endogenous inhibitors of collagenase not removed (active collagenase was al-
so measured without trypsin treatment)
Harris 1995 
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Time of measurement: baseline
Wound fluid sampling method: occlusive dressings (Tegaderm dressing, 4-6 hours (foam))
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias High risk No details on selection; wounds were classified into healing and non-healing
within a cohort of participants; not matched and longitudinal features not re-
ported.
Attrition bias Unclear risk Moderate: 2/12 participants in non-healing group missing. Unclear if this was
important
Prognostic factor mea-
surement
Unclear risk Moderate: MMP type not specified. 1995 study; unclear if measurement appro-
priate and insufficient details
Outcome measurement High risk Type of case-control study; healing and non-healing identified, but not
matched at the outset
Adjustment factors Unclear risk Moderate: at least half, but not all, key adjustment factors taken into account
in design or analysis (ulcers judged not to be "clinically" infected and con-
firmed in microbiology; infection taken into account in design)
Analysis and reporting Unclear risk Moderate: data had to be extracted from graph
Overall risk of bias High risk  
Harris 1995  (Continued)
 
 
Methods Prospective cohort study/case series
Setting: community wound clinic
Country: UK
Duration of follow-up: 36 weeks
Treatments: various dressings (NA ultra (4), wool padding (5), Zipzoc (2), Coltapaste), and compression
bandages (Litepress/Co-plus/crepe (2), Tensopress (2), Tubigrip, Elastocrepe)
Participants 7 participants with VLUs (no further details)
Age: not reported
Sex: not reported
Stage of ulcer: not reported
Ulcer duration: median (range): 3 years (13 months-8 years) (from IPD)
Ulcer size at baseline: not reported
Wound infection: not reported
Number of wounds: 7
HoJman 1999 
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Inclusion criteria: VLUs
Exclusion criteria: not reported
Prognostic factors Human neutrophil elastase (continuous data); from graph IPD. All participants had data at 4 weeks, so
this was selected as the baseline time; variability over time within participants. Measurement method
activity assay using selective substrate and measuring change in optical density.
Elastase activity determined using a standard curve generated with pure human neutrophil elastase
(Sigma, UK). Total elastase activities determined by correcting for total volume of wound fluid and
phosphate-buGered saline recovered from the bandage.
Time of measurement: baseline and weekly for 6 weeks
Wound fluid sampling method: entrapment in dressings (fluid harvested weekly from compression
bandages on dressing change)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias High risk Too few participants to be representative (7 participants with VLUs at 1 centre
were recruited into the study; study design changed so that measured healing
after 9 months rather than 6 weeks)
Attrition bias Low risk No missing data
Prognostic factor mea-
surement
High risk Moderate: protease levels recorded from bandages when dressings changed.
Protease levels will be influenced by how much remains on the dressings
Outcome measurement Unclear risk Moderate: unclear if blinded
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting High risk IPD given for outcome and individual protease levels given graphically. Not
all participants had protease levels at baseline, but results for all for week 4;
therefore, we selected this time of prognostic factor measurement
Overall risk of bias High risk  
HoJman 1999  (Continued)
 
 
Methods Prospective cohort study/case series
Setting: leg ulcer clinic
Country: UK
Duration of follow-up: 12 weeks
Treatments: not reported
Participants 10 participants with VLU and other wounds (7 VLU, 2 mixed A-V, 1 venous and diabetes)
Mean age: 72 (SD 9) years (calculated from IPD)
James 2003 
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Sex: not reported
Stage of ulcer: not reported
Ulcer duration: 45 (32) months (from IPD)
Ulcer size at baseline: 69 (73) cm2 (from IPD)
Wound infection: not reported
Number of wounds: 10
Inclusion criteria: chronic wound of lower leg
Exclusion criteria: not reported
Prognostic factors Human neutrophil elastase (continuous data). Measurement method ELISA: Merck kit. Diluted sample
in antibody-coated cuvette and second conjugate with alkaline phosphatase antibodies. Then p-nitro-
phenol phosphate substrate added, and absorbance measured in spectrophotometer. Likely to be in
an active form of protease.
Time of measurement: baseline
Wound fluid sampling method: occlusive dressings (Opsite (Smith & Nephew) 30-40 minutes)
Notes Minimal data collection because no direct results. Risk of bias assessments available on request
James 2003  (Continued)
 
 
Methods Prospective cohort study
Setting: attending outpatient phlebology clinic
Country: Poland
Duration of follow-up: 4 weeks
Treatments: all participants had amnion foetal membrane treatment (plus hydrocolloid and compres-
sion), shown to be an inhibitor of MMP activity (i.e. potential confounder)
Participants 25 participants with VLUs (CVLU; venous insufficiency aetiology, further confirmed by a duplex-Doppler
ultrasound examination)
Mean age: 76.3 (SD 12) years
Sex (M:F): 9:16
Stage of ulcer: C6 according to the CEAP classification
Wound infection: excluded if evident signs of infection (odorous, purulent exudates, wound necrosis
and significant pain)
Number of wounds: not reported
Inclusion criteria: chronic wound (> 6 months); surface area 10-100 cm2; delayed healing (healing rate <
10%/week) regardless of ≥ 2 weeks' treatment (screening period) of hydrocolloid dressing and effective
compression
Exclusion criteria: evident signs of wound infection (odorous, purulent exudates, wound necrosis and
significant pain), active DVT, leg ischaemia with ankle/brachial index < 0.8, poor tolerance of compres-
Litwiniuk 2012 
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sion, pregnancy, diabetes and other systemic diseases (particularly significant heart insufficiency) in
unstable stage and malignancy
Prognostic factors MMP-2 (continuous data); activity (ng/mL). Measurement method quantitative gelatin/SDS zymogra-
phy
Time of measurement: baseline and day 28
Wound fluid sampling method: not stated
Notes Limited data collection, no results. Risk of bias assessments available on request
Litwiniuk 2012  (Continued)
 
 
Methods RCT
Setting: clinical research centre associated with large university
Country: USA
Duration of follow-up: 8 weeks
Treatments: oral EPA + DHA vs placebo; all participants had silver-coated dressing beneath a 4-layer
compression dressing
Participants 40 participants with VLUs (5 with missing data)
Mean age: 60.3 (SD 12.6) years vs 60.9 (SD 11.8) years (EPA + DHA vs placebo)
Sex (M:F): 10:6 vs 11:8 (EPA + DHA vs placebo)
Stage of ulcer: not reported
Ulcer duration: EPA + DHA: < 6 months: 8 participants (50%) and > 6 months: 8 participants (50%); vs
placebo: < 6 months: 7 participants (37%) and > 6 months: 12 participants (63%)
Ulcer size at baseline: 15.6 (SD 34.4) cm2 vs 19.7 (SD 23.2) cm2 (EPA + DHA vs placebo)
Wound infection: not reported
Inclusion criteria: aged 18-81 years; ≥ 1 existing VLU between the ankle and knee for 3 months; pre-
scribed compression therapy; ABPI of 0.8; target wound ≥ 5 cm2
Exclusion criteria: allergic to fish or seafood; immunological-related conditions or chronic inflammato-
ry skin diseases; receiving blood thinning therapy or corticosteroids; required to take anti-inflammato-
ry drugs such as corticosteroids or ibuprofen more than twice a week
Group 1 received oral EPA + DHA; group 2 received placebo
Prognostic factors MMP-8 (continuous data). Measurement method ELISA: MMP-8, neutrophil collagenase, Biotrak ELISA
kit; optical density against a purified MMP-8 standard
Human neutrophil elastase (data). Measurement method activity assay: InnoZyme Human Neutrophil
Elastase Immunocapture Activity Assay Kit
Time of measurement: baseline, 28 weeks and 56 weeks
Wound fluid sampling method: occlusive dressings (Opsite (Smith & Nephew) 1-1.5 hours)
Notes  
McDaniel 2017 
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
43
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Participants were those scheduled to begin receiving CVLU treatment. RCT
population. Unclear whether this was representative.
Attrition bias Unclear risk Group 1: 5/21 participants missing (1 with health issues, 1 withdrew; 3 not
analysed); group 2: 0/19 participants missing
Prognostic factor mea-
surement
Unclear risk Unclear if active protease measured
Outcome measurement High risk Ulcer size stated to be measured by principal investigator
Adjustment factors High risk Inadequate: none of the key confounders taken into account in the design or
analysis
Analysis and reporting High risk Analysis as correlation used protease measurements at 4 weeks and 8 weeks
only (even though measured at baseline). Results not given separately for in-
tervention groups, even though intervention was designed to address pro-
tease levels
Overall risk of bias High risk  
McDaniel 2017  (Continued)
 
 
Methods Cohort comprised participants in the intervention arm of an RCT of oxyzyme/iodozyme vs control (usu-
al treatment)
Setting: community leg ulcer service
Country: UK
Duration of follow-up: 12 weeks
Treatments: oxyzyme/iodozyme plus secondary dressing (film, surgipad/thin foam according to exu-
date level). All used appropriate compression
Participants 47 participants with VLU or arterial leg ulcers (26 VLU, 21 mixed A-V)
Mean age: 69.7 (SD 13.2) years; similar for both groups
Sex (M:F): 23:24
Stage of ulcer: not reported
Ulcer duration: mean: 17.6 (SD 40.3) months
Ulcer size at baseline: mean 8.1 (SD 10.2) cm2
Wound infection: no cellulitis (exclusion criteria), but wound infection not mentioned
Number of wounds: unclear (1 limb per participant but (overall) 13 noted as having ulcer on contralat-
eral limb so possibly 113 wounds)
Inclusion criteria: aged ≥ 18 years, venous (ABPI > 0.8) or mixed (ABPI > 0.6) ulcer 2-50 cm2, mild or mod-
erate exudate, healthy peri-wound skin
MoJatt 2014a 
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Exclusion criteria: pregnancy, breastfeeding, acute DVT within 3 months, surgery for chronic venous in-
sufficiency within 2 months, surgery for peripheral arterial occlusive disease within 3 months, cellulitis,
thyroid treatment, known hypersensitivity to components of new dressings; peri-wound maceration or
uncontrolled varicose eczema around the ulceration
Prognostic factors MMP (unspecified) (dichotomous data); MMP activity. Measurement method enzyme detection device
for detecting or measuring the presence in a test sample of the activity of an enzyme capable of cleav-
ing a substrate: reverse ELTABA (Mologic Ltd.)
Time of measurement: baseline
Wound fluid sampling method: swabs (taken at dressing change)
Notes Results reported separately for the 2 randomised groups because oxyzyme/iodozyme suggested to be
protease modulating
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Low risk All participants considered who met the inclusion criteria
Attrition bias Unclear risk Moderate: 6/47 (13%) participants discontinued in intervention group; unclear
if important
Prognostic factor mea-
surement
Unclear risk Moderate: cut-oG defined on 0-10 scale; unclear if validated: score of ≥ 5 con-
sidered to be high protease activity
Outcome measurement High risk Not blinded, investigator present at all times and assessed the outcome
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting High risk Possible interaction with treatment (which proposed to be protease modulat-
ing); not taken into account in analysis
Overall risk of bias High risk  
MoJatt 2014a  (Continued)
 
 
Methods Cohort comprised participants in the control arm of an RCT of oxyzyme/iodozyme vs control (usual
treatment)
Setting: community leg ulcer service
Country: UK
Duration of follow-up: 12 weeks
Treatment: "standard care" + secondary dressing (film, surgipad/thin foam according to exudate level).
All used appropriate compression
Participants 53 participants with VLU or arterial leg ulcers (30 VLU, 23 mixed A-V)
Mean age: 69.4 (SD 13.35) years; similar for both groups
Sex (M:F): 29:24
Stage of ulcer: not reported
MoJatt 2014b 
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Ulcer duration: mean 20.0 (SD 56.5) months
Ulcer size at baseline: mean 7.1 (SD 10.0) cm2
Wound infection: no cellulitis (exclusion criteria), but wound infection not mentioned
Number of wounds: unclear (1 limb per participant but (overall) 13 noted as having ulcer on contralat-
eral limb so possibly 113 wounds)
Inclusion criteria: aged ≥ 18 years, venous (ABPI > 0.8) or mixed (ABPI > 0.6) ulcer 2-50 cm2, mild or mod-
erate exudate, healthy peri-wound skin
Exclusion criteria: pregnancy, breastfeeding, acute DVT within 3 months, surgery for chronic venous in-
sufficiency within 2 months, surgery for peripheral arterial occlusive disease within 3 months, cellulitis,
thyroid treatment, known hypersensitivity to components of new dressings; peri-wound maceration or
uncontrolled varicose eczema around the ulceration
Prognostic factors MMP (unspecified) (dichotomous data); MMP activity. Measurement method enzyme detection device
for detecting or measuring the presence in a test sample of the activity of an enzyme capable of cleav-
ing a substrate: reverse ELTABA (Mologic Ltd.)
Time of measurement: baseline
Wound fluid sampling method: swabs (taken at dressing change)
Notes Results reported separately for the 2 randomised groups because oxyzyme/iodozyme suggested to be
protease modulating
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Low risk All participants considered who met the inclusion criteria
Attrition bias Low risk 2/53 participants discontinued in control group
Prognostic factor mea-
surement
Unclear risk Moderate: cut-oG defined on 0-10 scale; unclear if validated: score of ≥ 5 con-
sidered to be high protease activity
Outcome measurement High risk Not blinded - investigator present at all times and assessed the outcome
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting Low risk Unlikely to be interaction with treatment
Overall risk of bias High risk  
MoJatt 2014b  (Continued)
 
 
Methods Prospective cohort
Setting: hospital venous unit
Country: Ireland
Duration of follow-up: 8 weeks
Treatments: Profore (Smith & Nephew) graduated compression bandaging
Mwaura 2006 
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Participants 40 participants with VLUs
Mean age: 60 years
Sex (M:F): 11:29
Stage of ulcer: CEAP stage 6
Ulcer duration: not reported
Ulcer size at baseline: not reported
Wound infection: not reported
Number of wounds: 40
Inclusion criteria: aged ≥ 50 years, VLU duration ≥ 8 weeks, ABPI > 0.9
Exclusion criteria: deep venous reflux, history of DVT, rheumatoid arthritis, diabetes, use of steroids, im-
munosuppression, chronic renal or liver disease, smoker
Prognostic factors MMP-2 (continuous data); ng/mL. Measurement method ELISA: R&D kit, immunoassay with optical den-
sity measurements
Time of measurement: baseline
Wound fluid sampling method: entrapment in dressings (wound fluid extracted from non-adherent
dressing that was in place for < 36 hours before clinic attendance)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Moderate: participants attending the venous unit were recruited; no further
details. Unclear whether representative
Attrition bias Low risk No missing data
Prognostic factor mea-
surement
Unclear risk Moderate: wound fluid extracted from dressings used for treatment; unclear if
this is reasonable
Outcome measurement Unclear risk Moderate: unclear if blinded
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting Low risk  
Overall risk of bias Unclear risk Moderate overall
Mwaura 2006  (Continued)
 
 
Methods Nested case-control design in a cross-sectional study, divided on clinical grounds into granulating and
inflammatory phases
Setting: not reported
RaJetto 2015 
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Country: not reported
Duration of follow-up: none, case-control
Participants 48 participants with VLUs
Mean age: 69.1 (SD 14.8) years vs 77.8 (SD 6.5) years (inflammatory vs granulating phase group); range
43-91 years
Sex: not reported
Stage of ulcer: 32 in inflammatory phase, 16 in granulating phase
Ulcer duration: not reported
Ulcer size at baseline: not reported
Wound infection: not reported
Number of wounds: unclear
Inclusion criteria: quote: "patients with VLU"
Exclusion criteria: not reported
Prognostic factors MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, MMP-13 (continuous data); concen-
tration pg/mL. Measurement method multiplex ELISA: wound fluid transferred in collecting tube with-
out additives or antiproteases. Centrifuged and supernatant frozen then concentration from multiplex
ELISA
Time of measurement: baseline
Wound fluid sampling method: entrapment in dressings (cotton gauze applied to wound bed until satu-
rated)
Notes Conference abstract
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias High risk Participants subdivided into those with granulating and inflammatory phase
wounds. Not matched and longitudinal features not reported
Attrition bias Low risk No missing data
Prognostic factor mea-
surement
Unclear risk Moderate: unclear if ELISA was adequate method and unclear if active or la-
tent protease
Outcome measurement High risk Type of case-control study; granulating and non-granulating identified, but
not matched at the outset. Not validated measure of healing
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis. Significant association of age with the outcome
Analysis and reporting High risk Results reported only for significant proteases (MMP-3, MMP-8, MMP-10 report-
ed as "non-significant")
Overall risk of bias High risk  
RaJetto 2015  (Continued)
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Methods Prospective cohort
Setting: single centre
Country: Italy
Duration of follow-up: 8 weeks
Treatments: all participants treated with appropriate surgery and compression (30-40 mmHg)
Participants 31 participants with VLUs (study additionally reported on a group without ulcers)
Mean age: 51.5 (SD 9) years, range 42-61 years
Sex (M:F): 9:22
Stage of ulcer: class 6 of CEAP (inclusion criterion)
Ulcer duration: > 6 weeks (inclusion criterion)
Ulcer size at baseline: median (range) 10.7 (2.1-17.5) cm2
Wound infection: no infection within 6 weeks (exclusion criterion)
Number of wounds: 31
Inclusion criteria: aged 20-70 years, VLU (class 6 CEAP), duration > 6 weeks, ABPI > 0.9
Exclusion criteria: arterial disease, infection within 6 weeks, connective tissue disorder, blood disorder,
cancer
Prognostic factors MMP-9 (continuous data); ng/total sample protein (μg). Measurement method ELISA: substrate and op-
tical density measurements. Reported as ng per total sample protein (μg)
Time of measurement: baseline, within 24 hours of surgery at 4 weeks, 8 weeks
Wound fluid sampling method: occlusive dressings (fluid collected after 4 hours)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Moderate: sample selection not stated
Attrition bias Low risk No missing data
Prognostic factor mea-
surement
Unclear risk Moderate: unclear if ELISA is adequate method and unclear if active or latent
protease
Outcome measurement High risk Not adjusted for baseline; unclear if blinded
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting Unclear risk Moderate: data extracted from graph
Overall risk of bias High risk  
Serra 2013 
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Methods Doxycycline arm of RCT (doxycycline vs control)
Setting: single clinical centre
Country: Italy
Duration of follow-up: 5 months
Treatments: all participants had basic treatment, including vein surgery if appropriate and compres-
sion stockings. Randomised to receive 3 months' course of doxycycline or standard care
Participants 32 participants with VLUs
Mean age: 50.5 (SD 8) years, range 41-60 years
Sex (M:F): 9:23
Stage of ulcer: class 6 of CEAP (inclusion criterion)
Ulcer duration: ≥ 6 weeks (inclusion criterion)
Ulcer size at baseline median (range): 12.9 (2.9-19.5) cm2
Wound infection: no infection within 6 weeks (inclusion criterion)
Number of wounds: unclear
Inclusion criteria: aged 20-70 years, VLU (class 6 CEAP), duration at least weeks, ABPI > 0.9
Exclusion criteria: arterial disease, infection within 6 weeks, connective tissue disorder, blood disorder,
cancer, gastroenteritis, allergy to tetracyclines
Prognostic factors MMP-9 (continuous data). Measurement method ELISA: kit from Amersham Pharmacia Biotech; same
approach as Serra 2013
Time of measurement: baseline, 4 weeks, 3 months, 5 months
Wound fluid sampling method: not stated
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Moderate: insufficient information to assess this domain. RCT, so may be less
representative
Attrition bias Low risk No missing data
Prognostic factor mea-
surement
Unclear risk Moderate: unclear if ELISA was adequate method and unclear if active or la-
tent protease
Outcome measurement High risk Not adjusted for baseline; unclear if blinded
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Serra 2015a 
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Analysis and reporting High risk Experimental arm may have interacted with protease levels. Not taken into ac-
count. Number of participants healing not reported, so SMD could not be ap-
plied
Overall risk of bias High risk  
Serra 2015a  (Continued)
 
 
Methods Control arm of RCT (doxycycline vs control)
Setting: single clinical centre
Country: Italy
Duration of follow-up: 5 months
Treatments: all participants had basic treatment, including vein surgery if appropriate and compres-
sion stockings. Randomised to receive a 3-month course of doxycycline or standard care
Participants 32 participants with VLUs in control group
Mean age: 51.3 (SD 7.5) years, range 46-57 years
Sex (M:F): 11:21
Stage of ulcer: class 6 of CEAP (inclusion criteria)
Ulcer duration: ≥ 6 weeks (inclusion criterion)
Ulcer size at baseline: median (range): 11.7 (3.1-17.5) cm2
Wound infection: no infection within 6 weeks (inclusion criterion)
Number of wounds: unclear
Inclusion criteria: aged 20-70 years, VLU (class 6 CEAP), duration at least weeks, ABPI > 0.9
Exclusion criteria: arterial disease, infection within 6 weeks, connective tissue disorder, blood disorder,
cancer, gastroenteritis, allergy to tetracyclines
Prognostic factors MMP-9 (continuous data). Measurement method ELISA: kit from Amersham Pharmacia Biotech; same
approach as Serra 2013
Time of measurement: baseline, 4 weeks, 3 months, 5 months
Wound fluid sampling method: not stated
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias Unclear risk Moderate: insufficient information to assess this domain. RCT, so may be less
representative
Attrition bias Low risk No missing data
Serra 2015b 
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
51
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Prognostic factor mea-
surement
Unclear risk Moderate: unclear if ELISA is adequate method and unclear if active or latent
protease
Outcome measurement High risk Not adjusted for baseline; unclear if blinded
Adjustment factors High risk None of the key adjustment factors taken into account in the design or analy-
sis
Analysis and reporting Unclear risk Moderate: number of participants healing not reported, so SMD could not be
applied. Treatment unlikely to interact with protease levels
Overall risk of bias High risk  
Serra 2015b  (Continued)
 
 
Methods RCT
Setting: single clinical centre
Country: Germany
Duration of follow-up: 12 weeks
Treatments: participants randomised to collagen/ORC matrix (protease modulating) and hydrocolloid
Participants 27 participants with VLUs
Mean age: 63 (SD 8) years
Sex: quote: "majority female"
Prognostic factors MMP-2 (continuous data); concentration. Measurement method ELISA and fluorogenic substrate assay:
sandwich ELISA for MMP-2, fluorogenic substrate assay for elastase and substrate/optical density mea-
surement for gelatinase (Gelatinase Activity Assay kit from Chemicon)
Time of measurement: baseline and 5, 14, 28, 42 and 56 days
Wound fluid sampling method: occlusive dressings (RELEASE dressing on wound then covered with oc-
clusive dressing (BIOCCLUSIVE) and leO for 6 hours)
Notes Limited data collection; no results. Risk of bias assessments available on request
Smeets 2008 
 
 
Methods Prospective cohort study
Setting: inpatients in hospital
Country: Australia
Duration of follow-up: 2 weeks
Treatments: bedrest
Participants 15 participants with VLUs or A-V mixed aetiology (7 VLU; 8 venous with minor arterial disease (Dopplers
> 0.6 and < 0.9))
Trengove 1999 
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Mean age: 77 (range 55-91) years
Sex (M:F): 10:5
Stage of ulcer: not reported
Ulcer duration: ≥ 3 months
Wound infection: not reported
Number of wounds: 15 (inferred)
Inclusion criteria: chronic leg ulcers in the gaiter region excluding the foot (all had venous disease and
had been treated as outpatients with compression to improve venous function; in all cases, ulcers had
failed to respond to treatment as defined by no reduction in size in > 3 months or a continued increase
in size of ulcer); arterial disease by ankle-brachial ratio < 0.9
Exclusion criteria: not reported
Prognostic factors MMP (unspecified); MMP-2, MMP-9 (implied) and elastase. Measurement method gelatin zymogra-
phy and fluorogenic substrate assay: Azcoll assay with spectrophotometer and compared to standard
curve for collagenase. µg protease equivalents/mL fluid; gelatin zymography; incubation with Illomo-
stat for specific MMP activity. Fluorogenic substrate assay: µg elastase/mL fluid (elastase)
Time of measurement: within 24 hours admission and after 2 weeks' bedrest
Wound fluid sampling method: occlusive dressings (transparent occlusive film (Opsite) placed over
wound in morning; fluid aspirated from beneath dressing after 1 hour)
Notes Limited data collection; no results. Risk of bias assessments available on request
Trengove 1999  (Continued)
 
 
Methods Prospective cohort study, VLU group (also group with acute wounds)
Setting: not reported
Country: Denmark
Duration of follow-up: 4 weeks
Participants 8 participants with VLUs (and 25 acute wounds)
Mean age: 82 (SD 20) years
Sex (M:F): 4:4
Prognostic factors MMP-9 (continuous data)
Time of measurement: baseline, 2 weeks, 4 weeks
Notes Minimal data collection because no results. Risk of bias assessments available on request
Trøstrup 2011 
 
 
Methods Prospective cohort study
Wysocki 1999 
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Setting: inpatients and outpatients in a large metropolitan university hospital and a Veterans Affairs
hospital
Country: USA
Duration of follow-up: 27 months
Participants 11 participants with VLUs
Mean age: 63.5 (SD 16.2) years
Sex (M:F): 8:3
Exclusion criteria: fluid collected only from ulcers with no sign or symptom of clinical wound infection
Prognostic factors uPA and MMP-9 (continuous data); protein expression. Measurement method: fluorogenic substrate
assay and fibrin overlap assay (uPA) and gelatin zymography (MMP-9): Spectrozyme PL assay, with
bovine plasminogen and 6-aminohexanoic acid to increase sensitivity; plasmin-specific amidolytic
chromogenic substrate, free p-nitroaniline from the substrate measured spectophotometrically. Also
fibrin overlap assay to distinguish active uPA
Time of measurement: baseline, and 3, 5, 16, 26, 27 months (data/gel image for 1 participant)
Wound fluid sampling method: occlusive dressings (semiocclusive polyurethane film dressing placed
over wound for 4-12 hours (but usually 1-3 hours sufficient))
Notes Minimal data collection because no results. Risk of bias assessments available on request
Wysocki 1999  (Continued)
ABPI: ankle-brachial pressure index; AUR: allantoin to uric acid ratio; A-V: arterial-venous; CEAP: classification system for venous disorders
based on their clinical, aetiological, anatomical and pathophysiological characteristics; CI: confidence interval; CVLU: chronic venous
leg ulcer; DHA: docosahexaenoic acid; DVT: deep vein thrombosis; ELISA: enzyme-linked immunosorbent assay; ELTABA: enzyme activity
assay; EPA: n-3 eicosapentaenoic acid; F: female; HR: hazard ratio; IPD: individual participant data; IQR: interquartile range; ORC: oxidised
regenerated cellulose; M: male; MMP: matrix metalloproteinase; PAI-1: plasminogen activator inhibitor-1; PAI-2: plasminogen activator
inhibitor-2; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation; SDS: sodium dodecyl sulphate; SE: standard error; SMD:
standardised mean diGerence; TIMP: tissue inhibitors of metalloproteinases; uPA: urokinase-type plasminogen activator; VLU: venous leg
ulcer; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahmad 2011 Ineligible study design
Alexewicz 2007 Sample or analysis technique were not eligible
Amato 2015 Ineligible study design
Anon 2008 Ineligible study design
Ayuk 2016 Ineligible study design
Barros 2012 Sample or analysis technique were not eligible
Bernatchez 2012 Ineligible outcome
Bigliardi 1955 Study conducted before relevant techniques available
Bogaczewicz 2004 Ineligible study design
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Study Reason for exclusion
Bohórquez-Sierra 2006 Ineligible study design
Budzyn-Napierala 2016 Ineligible population; not people with venous leg ulcer
Caimi 2015 Sample or analysis technique were not eligible
Clark 2001 Ineligible study design
Cook 2000 Ineligible study design
Cook 2009 Ineligible prognostic factor
Cullen 2002b Ineligible population
Da Silva 2014 Ineligible study design
Dalton 2005 Ineligible outcome
Derbyshire 2003 Ineligible study design
DuGy 2005 Ineligible study design
Eming 2006 Sample or analysis technique were not eligible
Eming 2008 Ineligible outcome
Failla 2008 Ineligible study design
Fernandez 2008 Sample or analysis technique were not eligible
Fisher 1998 Ineligible study design
Fray 2003 Preclinical animal study
Gacka 2004 Sample or analysis technique were not eligible
Gordon 1975 Ineligible study design; used as intervention
Grinnell 1992 Sample or analysis technique were not eligible
Grinnell 1998 Ineligible outcome
Hasmann 2011 Sample or analysis technique were not eligible
He 1999 Sample or analysis technique were not eligible
Herouy 2000a Ineligible study design; used as intervention
Herouy 2000b Ineligible study design
Herouy 2004 Sample or analysis technique were not eligible
Herrick 1997 Sample or analysis technique were not eligible
Hoffman 1998 Sample or analysis technique were not eligible
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Study Reason for exclusion
Honda 2011 Ineligible population
Huttunen 2000 Ineligible outcomes
Huttunen 2004 Ineligible outcomes
Huttunen 2005 Ineligible participants
Ibbotson 1994 Ineligible prognostic factor
Impola 2005 Ineligible outcomes
Ivins 2014 Ineligible study design
Karatepe 2010 Ineligible participants
Karim 2006 Ineligible outcomes
Kucharzewski 2005 Ineligible study design
Kucukguven 2013 Ineligible population
Körber 2006 Ineligible study design
Lantis 2011 Sample or analysis technique were not eligible
Ligi 2016 Ineligible study design
Lim 2010 Ineligible study design
Lotti 1995 Sample or analysis technique were not eligible
McCarty 2012 Ineligible study design
McCarty 2013 Ineligible study design
McInnes 2014 Ineligible outcome
Mirastschijski 2002 Ineligible population
Mirshahi 1995 Sample or analysis technique were not eligible
Moor 2009 Ineligible outcome
Moore 2007 Ineligible study design
Nielsen 1992 Sample or analysis technique were not eligible
Norgauer 2002 Sample or analysis technique were not eligible
Nwomeh 1999 Ineligible study design
Ovington 2001 Ineligible study design
Palolahti 1993 Ineligible outcome
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Study Reason for exclusion
Phillips 2007 Ineligible study design
Pirila 2007 Sample or analysis technique were not eligible
Raffetto 2014 Ineligible study design
Rayment 2008 Ineligible outcome
Rayment 2009 Ineligible study design
Rechardt 2000 Sample or analysis technique were not eligible
Rogers 1999 Ineligible study design
Saarialho-Kere 1998 Sample or analysis technique were not eligible
Salgado 2017 Wound biopsy and proteases not investigated for clinical part of the study
Schmid 1999 Ineligible outcome
Schmidtchen 2000 Ineligible outcome
Schmidtchen 2003 Ineligible study design
Schultz 2004 Ineligible population
Senet 2003 Ineligible prognostic factor
Serena 2016 Healing rate measured before the start of the study; so cross-sectional design
Serra 2014 Ineligible population
Serra 2015c Ineligible study design
Serra 2016a Ineligible study design
Serra 2016b Sample or analysis technique were not eligible
Serra 2017 Sample or analysis technique were not eligible
Shields 1994 Ineligible population
Singh 2010 Ineligible study design
Stacey 1993 Sample or analysis technique were not eligible
Stacey 2000 Sample or analysis technique were not eligible
Stojadinovic 2014 Ineligible prognostic factor
Tarlton 1999 Ineligible study design
Tauzin 2014 Sample or analysis technique were not eligible
Turio 2002 Sample or analysis technique were not eligible
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Study Reason for exclusion
Ulrich 2005 Sample or analysis technique were not eligible
Vaalamo 1996 Sample or analysis technique were not eligible
Vaalamo 1997 Sample or analysis technique were not eligible
Vaalamo 1999 Sample or analysis technique were not eligible
Vahlquist 2000 Ineligible study design
Van Bergen 1996 Sample or analysis technique were not eligible
Varelias 2002 Ineligible population
Varelias 2006 Ineligible population
Weckroth 1996 Ineligible study design
Weckroth 2004 Sample or analysis technique were not eligible
Widgerow 2011 Ineligible study design
Wlaschek 1997 Ineligible prognostic factor
Wysocki 1993 Ineligible outcome
Wysocki 1996 Ineligible outcome
Zamboni 2005 Ineligible population
Zeegelaar 1997 Sample or analysis technique were not eligible
Zillmer 2011 Ineligible outcome
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Notes Conference abstract. Participants with venous leg ulcers treated with collagen/oxidised regener-
ated cellulose for 4 weeks and elastase levels measured. Outcome was response to treatment (un-
clear how this was measured). Few details
Cullen 2009 
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Comparison 1.   Protease activity continuous
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 t-test assocation of protease level and
healing (dichotomous)
6   Std. Mean Difference (IV, Fixed, 95% CI) Totals not se-
lected
1.1 Completely healed vs non-healed 2   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Degrading MMPs: (gelatinases/metal-
loelastase) healing vs non-healing
3   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Reparative MMPs: (collagenases/ma-
trilysin) healing vs non-healing
2   Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 t-test association of protease level and
healing: high (≥ 1 cm2/week) vs low (< 1
cm2/week) healing
3   Mean Difference (Fixed, 95% CI) Totals not se-
lected
2.1 With doxycycline treatment 1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 With standard care treatment 1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Treatment not reported (other than
compression)
1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Correlation coefficients: protease levels
and change in size
3   Correlation coefficient (Fixed, 95% CI) Totals not se-
lected
3.1 Change in MMP-2 level vs reduction in
ulcer size
1   Correlation coefficient (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Change in MMP-9 level vs reduction in
ulcer size
1   Correlation coefficient (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 MMP-8 level at 4 weeks vs % reduction
in size at 8 weeks
1   Correlation coefficient (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Elastase level at 4 weeks vs % reduc-
tion in size at 8 weeks
1   Correlation coefficient (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Elastase at 4 weeks vs % change in
size at 9 months
1   Correlation coefficient (Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Protease activity continuous, Outcome
1 t-test assocation of protease level and healing (dichotomous).
Study or subgroup Healing No healing Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.1.1 Completely healed vs non-healed  
Ahmad 2015 9 0.4 (0.5) 21 0.2 (0.1) 0.72[-0.08,1.53]
Hoffman 1999 3 9.5 (7.1) 4 53 (54.3) -0.87[-2.51,0.78]
Lower protease 105-10 -5 0 Higher protease
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Study or subgroup Healing No healing Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
   
1.1.2 Degrading MMPs: (gelatinases/metalloelastase) healing vs non-healing  
Mwaura 2006 20 117 (61) 20 133 (12) -0.36[-0.98,0.27]
Raffetto 2015 16 173900 (47170) 32 483100 (68190) -4.9[-6.08,-3.71]
Raffetto 2015 16 22780 (7478) 32 67550 (12350) -4[-5.03,-2.97]
Raffetto 2015 16 14700 (65300) 32 943900 (119600) -8.7[-10.62,-6.79]
Serra 2013 13 240.2 (41.5) 7 249.1 (33.9) -0.22[-1.14,0.7]
Serra 2013 11 247.8 (42.5) 7 249.1 (33.9) -0.03[-0.98,0.92]
   
1.1.3 Reparative MMPs: (collagenases/matrilysin) healing vs non-healing  
Harris 1995 6 0.6 (0.8) 12 0.4 (0.4) 0.3[-0.69,1.28]
Raffetto 2015 16 3072 (1076) 32 1212 (609) 2.31[1.54,3.08]
Raffetto 2015 16 10290 (3775) 32 3093 (930) 3.1[2.21,3.98]
Raffetto 2015 16 142800 (26730) 32 79460 (26370) 2.35[1.58,3.13]
Lower protease 105-10 -5 0 Higher protease
 
 
Analysis 1.2.   Comparison 1 Protease activity continuous, Outcome 2 t-test association
of protease level and healing: high (≥ 1 cm2/week) vs low (< 1 cm2/week) healing.
Study or subgroup High healing Low healing Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.2.1 With doxycycline treatment  
Serra 2015a 5 27 -8.7 (15.001) -8.7[-38.1,20.7]
   
1.2.2 With standard care treatment  
Serra 2015b 0 0 -6.3 (17.263) -6.3[-40.13,27.53]
   
1.2.3 Treatment not reported (other than compression)  
Serra 2013 0 0 -7.7 (17.221) -7.68[-41.43,26.07]
Lower protease 10050-100 -50 0 Higher protease
 
 
Analysis 1.3.   Comparison 1 Protease activity continuous, Outcome
3 Correlation coeJicients: protease levels and change in size.
Study or subgroup not applicable not applicable Correlation
coefficient
Correlation coefficient Correlation coefficient
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.3.1 Change in MMP-2 level vs reduction in ulcer size  
Gohel 2008 0 0 0 (0) Not estimable
   
1.3.2 Change in MMP-9 level vs reduction in ulcer size  
Gohel 2008 0 0 0 (0) Not estimable
   
1.3.3 MMP-8 level at 4 weeks vs % reduction in size at 8 weeks  
McDaniel 2017 0 0 -0.4 (0.2) -0.36[-0.75,0.03]
   
Less healing 10.5-1 -0.5 0 More healing
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Study or subgroup not applicable not applicable Correlation
coefficient
Correlation coefficient Correlation coefficient
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.3.4 Elastase level at 4 weeks vs % reduction in size at 8 weeks  
McDaniel 2017 0 0 -0 (0.171) -0.02[-0.35,0.31]
   
1.3.5 Elastase at 4 weeks vs % change in size at 9 months  
Hoffman 1999 0 0 -0.8 (0.441) -0.78[-1.64,0.08]
Hoffman 1999 0 0 -0 (0.383) -0[-0.75,0.75]
Less healing 10.5-1 -0.5 0 More healing
 
 
Comparison 2.   Protease activity dichotomous
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Association of healing with elevated protease level; by
protease modulating (PM) intervention
3   Risk Ratio (Fixed, 95% CI) Totals not se-
lected
1.1 Elastase > 25 mU/100 μL vs ≤ 25 mU/100 μL + PM inter-
vention
1   Risk Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 MMP (unspecified) level ≥ 5 (0-10 scale) vs < 5 + possi-
ble PM intervention
1   Risk Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 MMP (unspecified) level ≥ 5 (0-10 scale) vs < 5 + non-PM
intervention
1   Risk Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Protease activity dichotomous, Outcome 1 Association
of healing with elevated protease level; by protease modulating (PM) intervention.
Study or subgroup     log[Risk Ratio] Risk Ratio Risk Ratio
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
2.1.1 Elastase > 25 mU/100 μL vs ≤ 25 mU/100 μL + PM intervention  
Cullen 2012 13 43 0.3 (0.2) 1.32[0.89,1.96]
   
2.1.2 MMP (unspecified) level ≥ 5 (0-10 scale) vs < 5 + possible PM intervention  
Moffatt 2014a 28 19 0.1 (0.307) 1.06[0.58,1.93]
   
2.1.3 MMP (unspecified) level ≥ 5 (0-10 scale) vs < 5 + non-PM intervention  
Moffatt 2014b 0 0 -0.2 (0.279) 0.83[0.48,1.43]
Less healing 100.1 50.2 20.5 1 More healing
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Central Register of Controlled Trials (CENTRAL)(Issue 2 of 12, February 2018)
#1 MeSH descriptor: [Leg Ulcer] explode all trees
#2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris or foot ulcer*):ti,ab,kw
#3 {or #1-#2}
#4 MeSH descriptor: [Protease Inhibitors] explode all trees
#5 MeSH descriptor: [Peptide Hydrolases] explode all trees
#6 (proteas* or proteinas* or metalloproteas* or metalloproteinas* or mmp or timp or gelatinase* or collagenase* or stromelysin* or
metalloelastase* or matrilysin* or enamelysin* or epilysin* or endometase* or hne):ti,ab,kw
#7 (neutrophil elastase* or cathepsin* or urokinase type plasminogen activator* or upa or enzyme* activit* or proteolytic* or
endopeptidase* or peptide peptidohydrolase* or caseinase* or peptidyl peptid* hydrolase* or peptidylpeptide hydrolase*):ti,ab,kw
#8 (proteolytic enzyme* or peptide hydrolase* or secretase* or deubiquitinase* or keratinase* or proteasome* or peptidase* or
complestatin* or ecarin* or rupintrivir* or Acrosin* or Aminopeptidase* or Ancrod* or Anistreplase*):ti,ab,kw
#9 (Antigen* and CD13):ti,ab,kw
#10 (Ataxin 3 or Batroxobin* or Botulinum Toxin* or Brinolase* or Bromelain* or Calpain* or Carboxypeptidase* or Caspase* or Chymase*
or Chymopapain* or Chymosin* or Chymotrypsin* or Coagulase* or Complement Factor* or Dipeptidase*):ti,ab,kw
#11 (Dipeptidyl-Peptidase* or Enteropeptidase* or Esteroprotease* or Exopeptidase* or Factor IXa or Factor VIIa or Factor Xa or Factor Xia
or Factor XIIa or Fibrinolysin* or Ficain* or Furin* or gamma-Glutamyl Hydrolase* or Granzyme* or Insulysin*):ti,ab,kw
#12 (Kallikrein* or Lactoferrin* or Lysostaphin* or Metalloexopeptidase* or Myeloblastin* or Neprilysin* or Papain* or Pepsin A
or Plasminogen Activator* or Prekallikrein* or Pronase* or Proprotein Convertase* or Renin* or Separase* or Streptodornase* or
Streptokinase* or Subtilisin* or Thermolysin* or Thrombin* or Trypsin* or Tryptases*):ti,ab,kw
#13 {or #4-#12}
#14 #3 and #13
Ovid MEDLINE
(1946 to January week 4 2018)
1 exp Leg Ulcer/ (21282)
2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris
or foot ulcer*).tw. (13385)
3 1 or 2 (24989)
4 exp Peptide Hydrolases/ (557476)
5 exp Protease Inhibitors/ (207571)
6 (proteas* or proteinas*).tw. (213317)
7 metalloproteas*.tw. (10342)
8 metalloproteinas*.tw. (59177)
9 mmp.tw. (47220)
10 timp.tw. (11539)
11 gelatinase*.tw. (8630)
12 collagenase*.tw. (21223)
13 stromelysin*.tw. (2216)
14 metalloelastase*.tw. (235)
15 matrilysin*.tw. (634)
16 enamelysin*.tw. (129)
17 epilysin*.tw. (30)
18 endometase*.tw. (20)
19 hne.tw. (3945)
20 neutrophil elastase*.tw. (4194)
21 cathepsin*.tw. (21302)
22 urokinase-type plasminogen activator*.tw. (4923)
23 upa.tw. (5755)
24 enzyme* activit*.tw. (105506)
25 proteolytic*.tw. (73550)
26 endopeptidase*.tw. (8884)
27 peptide peptidohydrolase*.tw. (5)
28 caseinase*.tw. (180)
29 peptidyl peptid* hydrolase*.tw. (6)
30 peptidylpeptide hydrolase*.tw. (2)
31 proteolytic enzyme*.tw. (11483)
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32 peptide hydrolase*.tw. (385)
33 secretase*.tw. (7993)
34 deubiquitinase*.tw. (1176)
35 keratinase*.tw. (331)
36 proteasome*.tw. (34437)
37 peptidase*.tw. (19353)
38 complestatin*.tw. (39)
39 ecarin*.tw. (286)
40 rupintrivir*.tw. (32)
41 Acrosin*.tw. (916)
42 Aminopeptidase*.tw. (11845)
43 Ancrod*.tw. (395)
44 Anistreplase*.tw. (198)
45 (Antigen* adj2 CD13).tw. (228)
46 Ataxin-3.tw. (551)
47 Batroxobin*.tw. (279)
48 Botulinum Toxin*.tw. (11872)
49 Brinolase*.tw. (13)
50 Bromelain*.tw. (1336)
51 Calpain*.tw. (9151)
52 Carboxypeptidase*.tw. (8311)
53 Caspase*.tw. (92315)
54 Chymase*.tw. (1980)
55 Chymopapain*.tw. (747)
56 Chymosin*.tw. (514)
57 Chymotrypsin*.tw. (18311)
58 Coagulase*.tw. (11196)
59 Complement Factor*.tw. (4054)
60 Dipeptidase*.tw. (1383)
61 Dipeptidyl-Peptidase*.tw. (6459)
62 Enteropeptidase*.tw. (183)
63 Esteroprotease*.tw. (58)
64 Exopeptidase*.tw. (787)
65 Factor IXa.tw. (730)
66 Factor VIIa.tw. (3228)
67 Factor Xa.tw. (7194)
68 Factor XIa.tw. (487)
69 Factor XIIa.tw. (525)
70 Fibrinolysin*.tw. (677)
71 Ficain*.tw. (2)
72 Furin*.tw. (2730)
73 gamma-Glutamyl Hydrolase*.tw. (193)
74 Granzyme*.tw. (5802)
75 Insulysin*.tw. (57)
76 Kallikrein*.tw. (10812)
77 Lactoferrin*.tw. (7648)
78 Lysostaphin*.tw. (593)
79 Metalloexopeptidase*.tw. (24)
80 Myeloblastin*.tw. (53)
81 Neprilysin*.tw. (1249)
82 Papain*.tw. (8656)
83 Pepsin A.tw. (208)
84 Plasminogen Activator*.tw. (38347)
85 Prekallikrein*.tw. (1609)
86 Pronase*.tw. (5608)
87 Proprotein Convertase*.tw. (2387)
88 Renin*.tw. (53044)
89 Separase*.tw. (450)
90 Streptodornase*.tw. (567)
91 Streptokinase*.tw. (7558)
92 Subtilisin*.tw. (5888)
93 Thermolysin*.tw. (2353)
Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
63
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
94 Thrombin*.tw. (47618)
95 Trypsin*.tw. (61663)
96 Tryptases*.tw. (218)
97 or/4-96 (1067636)
98 3 and 97 (736)
99 exp animals/ not humans.sh. (4861175)
100 98 not 99 (718)
Ovid Embase
(1974 to 2018 February (week 6))
1 leg ulcer/ or foot ulcer/ or leg varicosis/ (20352)
2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris
or foot ulcer*).tw. (15795)
3 1 or 2 (25225)
4 exp Proteinase/ (669495)
5 exp Proteinase Inhibitor/ (311383)
6 (proteas* or proteinas*).tw. (213747)
7 metalloproteas*.tw. (10676)
8 metalloproteinas*.tw. (63056)
9 mmp.tw. (55120)
10 timp.tw. (13502)
11 gelatinase*.tw. (9437)
12 collagenase*.tw. (22992)
13 stromelysin*.tw. (2117)
14 metalloelastase*.tw. (229)
15 matrilysin*.tw. (588)
16 enamelysin*.tw. (86)
17 epilysin*.tw. (29)
18 endometase*.tw. (19)
19 hne.tw. (4272)
20 neutrophil elastase*.tw. (4834)
21 cathepsin*.tw. (21650)
22 urokinase-type plasminogen activator*.tw. (4993)
23 upa.tw. (6460)
24 enzyme* activit*.tw. (105378)
25 proteolytic*.tw. (69113)
26 endopeptidase*.tw. (8538)
27 peptide peptidohydrolase*.tw. (1)
28 caseinase*.tw. (194)
29 peptidyl peptid* hydrolase*.tw. (7)
30 peptidylpeptide hydrolase*.tw. (3)
31 proteolytic enzyme*.tw. (11539)
32 peptide hydrolase*.tw. (333)
33 secretase*.tw. (8796)
34 deubiquitinase*.tw. (1058)
35 keratinase*.tw. (413)
36 proteasome*.tw. (34829)
37 peptidase*.tw. (19823)
38 complestatin*.tw. (42)
39 ecarin*.tw. (421)
40 rupintrivir*.tw. (36)
41 Acrosin*.tw. (954)
42 Aminopeptidase*.tw. (11341)
43 Ancrod*.tw. (443)
44 Anistreplase*.tw. (216)
45 (Antigen* adj2 CD13).tw. (246)
46 Ataxin-3.tw. (498)
47 Batroxobin*.tw. (345)
48 Botulinum Toxin*.tw. (15575)
49 Brinolase*.tw. (14)
50 Bromelain*.tw. (1401)
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51 Calpain*.tw. (9068)
52 Carboxypeptidase*.tw. (7525)
53 Caspase*.tw. (103048)
54 Chymase*.tw. (2100)
55 Chymopapain*.tw. (732)
56 Chymosin*.tw. (507)
57 Chymotrypsin*.tw. (16352)
58 Coagulase*.tw. (13204)
59 Complement Factor*.tw. (4515)
60 Dipeptidase*.tw. (1247)
61 Dipeptidyl-Peptidase*.tw. (7601)
62 Enteropeptidase*.tw. (196)
63 Esteroprotease*.tw. (56)
64 Exopeptidase*.tw. (752)
65 Factor IXa.tw. (704)
66 Factor VIIa.tw. (3922)
67 Factor Xa.tw. (8476)
68 Factor XIa.tw. (486)
69 Factor XIIa.tw. (515)
70 Fibrinolysin*.tw. (481)
71 Ficain*.tw. (2)
72 Furin*.tw. (2584)
73 gamma-Glutamyl Hydrolase*.tw. (195)
74 Granzyme*.tw. (7374)
75 Insulysin*.tw. (40)
76 Kallikrein*.tw. (10846)
77 Lactoferrin*.tw. (7803)
78 Lysostaphin*.tw. (565)
79 Metalloexopeptidase*.tw. (21)
80 Myeloblastin*.tw. (61)
81 Neprilysin*.tw. (1442)
82 Papain*.tw. (8141)
83 Pepsin A.tw. (201)
84 Plasminogen Activator*.tw. (41285)
85 Prekallikrein*.tw. (1643)
86 Pronase*.tw. (5204)
87 Proprotein Convertase*.tw. (2469)
88 Renin*.tw. (59567)
89 Separase*.tw. (423)
90 Streptodornase*.tw. (482)
91 Streptokinase*.tw. (8008)
92 Subtilisin*.tw. (5678)
93 Thermolysin*.tw. (2079)
94 Thrombin*.tw. (55364)
95 Trypsin*.tw. (59501)
96 Tryptases*.tw. (211)
97 or/4-96 (1190187)
98 3 and 97 (1209)
99 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or
nonhuman/ (24411894)
100 human/ or human cell/ (18421186)
101 99 and 100 (18374370)
102 99 not 101 (6037524)
103 98 not 102 (1166)
EBSCO CINAHL Plus
(Inception to February 2018)
S1 (MH “Leg Ulcer+”)
S2 TI ( (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris or foot ulcer*) ) OR AB
( (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris or foot ulcer*) )
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S3 S1 OR S2
S4 (MH "Protease Inhibitors+") OR (MH "Peptide Hydrolases+")
S5 TI ( (proteas* or proteinas*) ) OR AB ( (proteas* or proteinas*) )
S6 TI ((metalloproteas* or metalloproteinas*)) OR AB ((metalloproteas* or metalloproteinas*))
S7 TI ((mmp or timp)) OR AB ((mmp or timp))
S8 TI ((gelatinase* OR collagenase* OR stromelysin* OR metalloelastase* OR matrilysin*)) OR AB ((gelatinase* OR collagenase* OR
stromelysin* OR metalloelastase* OR matrilysin*))
S9 TI ((enamelysin* OR epilysin* OR endometase* OR hne OR neutrophil elastase* OR cathepsin*)) OR AB ((enamelysin* OR epilysin* OR
endometase* OR hne OR neutrophil elastase* OR cathepsin*))
S10 TI ((urokinase type plasminogen activator* or upa or enzyme* activit* or proteolytic* or endopeptidase*)) OR AB ((urokinase type
plasminogen activator* or upa or enzyme* activit* or proteolytic* or endopeptidase*))
S11 TI ((peptide peptidohydrolase* or caseinase* or peptidyl peptid* hydrolase* or peptidylpeptide hydrolase* or proteolytic enzyme* or
peptide hydrolase* or secretase*)) OR AB ((peptide peptidohydrolase* or caseinase* or peptidyl peptid* hydrolase* or peptidylpeptide
hydrolase* or proteolytic enzyme* or peptide hydrolase* or secretase*))
S12 TI ((deubiquitinase* or keratinase* or proteasome* or signal peptidase* or complestatin* or ecarin* or rupintrivir*)) OR AB
((deubiquitinase* or keratinase* or proteasome* or signal peptidase* or complestatin* or ecarin* or rupintrivir*))
S13 TI ((Acrosin* or Aminopeptidase* or Ancrod* or Anistreplase*)) OR AB ((Acrosin* or Aminopeptidase* or Ancrod* or Anistreplase*))
S14 TI (Antigen* and CD13) OR AB (Antigen* and CD13)
S15 TI ((Ataxin 3 or Batroxobin* or Botulinum Toxin* or Brinolase* or Bromelain* or Calpain* or Carboxypeptidase* or Caspase*)) OR AB
((Ataxin 3 or Batroxobin* or Botulinum Toxin* or Brinolase* or Bromelain* or Calpain* or Carboxypeptidase* or Caspase*))
S16 TI ((Chymase* or Chymopapain* or Chymosin* or Chymotrypsin* or Coagulase* or Complement Factor* or Dipeptidase* or Dipeptidyl
Peptidase*)) OR AB ((Chymase* or Chymopapain* or Chymosin* or Chymotrypsin* or Coagulase* or Complement Factor* or Dipeptidase*
or Dipeptidyl Peptidase*))
S17 TI ((Enteropeptidase* or Esteroprotease* or Exopeptidase* or Factor IXa or Factor VIIa or Factor Xa or Factor Xia or Factor XIIa or
Fibrinolysin*)) OR AB ((Enteropeptidase* or Esteroprotease* or Exopeptidase* or Factor IXa or Factor VIIa or Factor Xa or Factor Xia or Factor
XIIa or Fibrinolysin*))
S18 TI ((Ficain* or Furin* or gamma Glutamyl Hydrolase* or Granzyme* or Insulysin* or Kallikrein* or Lactoferrin* or Lysostaphin* or
Metalloexopeptidase* or Myeloblastin*)) OR AB ((Ficain* or Furin* or gamma Glutamyl Hydrolase* or Granzyme* or Insulysin* or Kallikrein*
or Lactoferrin* or Lysostaphin* or Metalloexopeptidase* or Myeloblastin*))
S19 TI ((Neprilysin* or Papain* or Pepsin A or Plasminogen Activator* or Prekallikrein* or Pronase* or Proprotein Convertase*)) OR AB
((Neprilysin* or Papain* or Pepsin A or Plasminogen Activator* or Prekallikrein* or Pronase* or Proprotein Convertase*))
S20 TI ((Renin* or Separase* or Streptodornase* or Streptokinase* or Subtilisin* or Thermolysin* or Thrombin* or Trypsin* or Tryptases*))
OR AB ((Renin* or Separase* or Streptodornase* or Streptokinase* or Subtilisin* or Thermolysin* or Thrombin* or Trypsin* or Tryptases*))
S21 (S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20)
S22 S3 and S21
Appendix 2. Quality In Prognosis Studies (QUIPS): risk of bias assessment, modified for this review
We assessed risk of bias for each study for each prognostic factor–outcome combination, considering each of six domains.
Domain 1. Study participation
This domain assessed whether the study sample was representative of the population of interest (source population).
Low risk of bias
The relationship between the prognostic factor and the outcome was unlikely to be diGerent for participating individuals and eligible non-
participating individuals. We made an assignment of low risk of bias if all the following requirements were met:
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• the study sample was consecutively or randomly recruited from the target population or, for case-control studies, the cases and controls
were from similar populations;• participants were representative of the review population of interest:* people with venous leg ulcers;* study follow-up was adequate for healing to occur and reverse association to be avoided; a minimum of two months' follow-up;* participants were not diGerent from eligible non-participants in terms of the key prognostic factors (Appendix 3);* the participation rate was high; review authors' judgement.
High risk of bias
The relationship between the prognostic factor and the outcome was very likely to be diGerent for participating individuals and eligible
non-participating individuals. We noted that prognostic studies based on data from randomised trial evidence would oOen have selected
participants and we considered the RCT inclusion criteria, as appropriate (Iorio 2015). We made an assignment of high risk of bias if any of
the following statements applied and we considered there was a likely high risk of bias as a consequence:
• the sample was selectively recruited. For case-control studies, cases and controls were not from similar source populations;• participants were not representative of the review population of interest:* participants had very diGerent characteristics from eligible non-participants in terms of the key prognostic factors;* study follow-up was inadequate for events to occur or reverse association was possible (less than two months) (or both);* the participation rate was low.
Moderate risk of bias
The relationship between the prognostic factor and the outcome may have been diGerent for participating individuals and eligible non-
participating individuals, but there was insuGicient information to make a judgement of low or high risk of bias, or we were uncertain
whether the quality issue was likely to lead to high risk of bias.
Domain 2. Study attrition
The study attrition domain addressed whether participants completing the study (i.e. with follow-up data) represented the baseline
sample.
Low risk of bias
The relationship between the prognostic factor and the outcome was unlikely to be diGerent for completing and non-completing
participants. We made an assignment of low risk of bias if any one of the following was true:
• no missing outcome data or adequate response rate;• reasons for missing outcome data were unlikely to be related to true outcome (for survival data, censoring was unlikely to be introducing
bias), e.g. missing at random;• missing outcome data were balanced in numbers across categorical prognostic groups, with similar reasons for missing data across
groups in terms of the key prognostic factors;• missing data were imputed using appropriate methods.
High risk of bias
The relationship between the prognostic factor and the outcome was very likely to be diGerent for completing and non-completing
participants. We made an assignment of high risk of bias if any of the following statements applies and we considered there was a likely
high risk of bias as a consequence:
• reasons for missing data were likely to be related to the true outcome or the prognostic factor, with either imbalance in numbers or
reasons for missing data across categorical prognostic groups in terms of the key prognostic factors;• high levels of missing data;• potentially inappropriate application of simple imputation.
Moderate risk of bias
The relationship between the prognostic factor and the outcome may have been diGerent for completing and non-completing participants,
but there was insuGicient information to make a judgement of low or high risk of bias, or we were uncertain whether the quality issue was
likely to lead to high risk of bias.
Domain 3. Prognostic factor measurement
The prognostic factor measurement domain addressed adequacy of measurement of the prognostic factor of interest.
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Low risk of bias
The measurement of the prognostic factor was unlikely to be diGerent for diGerent outcome levels (i.e. healed or not healed). We made an
assignment of low risk of bias if all the following requirements were met:
• a clear definition or description of the prognostic factor was given;• the prognostic factor was measured similarly for all participants (same method and setting);• a valid and reliable measure was used;• continuous variables were used or appropriate cut-oG points were applied;• an adequate proportion of the sample had complete data for the prognostic factor;• appropriate imputation of missing values was done.
High risk of bias
The measurement of the prognostic factor was very likely to be diGerent for diGerent outcome levels (i.e. healed or not healed). We made
an assignment of high risk of bias if any of the following statements applied and we considered there was a likely high risk of bias as a
consequence:
• an unreliable or non-validated method was used to measure the prognostic factor (non-diGerential misclassification bias);• diGerent approaches to prognostic factor measurement were taken for participants with diGerent outcomes;• details about the prognostic factor were based on recall or potentially unreliable participant records (reporting bias);• inappropriate cut-oG points were used;• the proportion of the sample with complete data for the prognostic factor was inadequate.
Moderate risk of bias
The measurement of the prognostic factor may have been diGerent for diGerent outcome levels (e.g. healed or not healed) or for diGerent
risks of the outcome, but there was insuGicient information to make a judgement of low or high risk of bias, or we were uncertain whether
the quality issue was likely to lead to high risk of bias.
Domain 4. Outcome measurement
The outcome measurement domain addressed the adequacy of outcome measurement.
Low risk of bias
The measurement of the outcome was unlikely to be diGerent with respect to diGerent baseline levels of the prognostic factor. We made
an assignment of low risk of bias if all the following requirements were met:
• a clear definition or description of the outcome was given (including duration of follow-up);• the outcome of interest was measured similarly for all participants (same method and setting);• a valid and reliable outcome measure was used (including blinding and avoidance of recall methods).
High risk of bias
The measurement of the outcome was very likely to be diGerent with respect to diGerent baseline levels of the prognostic factor. We made
an assignment of high risk of bias if any of the following statements applied and we considered there was a likely high risk of bias as a
consequence:
• diGerent methods were used for participants with diGerent values of the prognostic factor;• measurement of the outcome was not blinded;• an unreliable or non-validated outcome measure was used;• the outcome measure relied on participant/carer recall;• measurement error varied according to the prognostic factor level.
Moderate risk of bias
The measurement of the outcome may have been diGerent for diGerent baseline levels of the prognostic factor, but there was insuGicient
information to make a judgement of low or high risk of bias, or we were uncertain whether the quality issue was likely to lead to high risk
of bias.
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Domain 5. Adjustment
The adjustment domain addressed potential factors that may have distorted the relationship between prognostic factor and outcome.
Considerations in this domain helped the assessor judge whether another factor may have explained the study’s reported association (see
Appendix 3).
Our literature review provided little evidence to enable us to define key adjustment factors, but in this domain, we considered whether the
included studies took into account age and infection (Appendix 3). We reported and compared adjusting factors used across the studies.
We also examined whether there were diGerences between adjusted and unadjusted analyses.
Low risk of bias
Important key adjustment factors were appropriately accounted for. We made an assignment of low risk of bias if all the following
requirements were met:
• key adjustment factors were taken into account in the study design (e.g. matching, stratification) or in the analysis (e.g. multivariable
regression) or adjusted and unadjusted analyses were compared and diGerences identified;• key adjustment factors were measured adequately;• measurement of all key adjustment factors was valid and reliable (including blinding);• methods and settings for measurement of adjustment factors were the same for all participants;• appropriate imputation methods were used;• account was taken of treatments in the analysis if appropriate.
High risk of bias
The observed eGect of the prognostic factor on the outcome was very likely to be distorted by another factor related to the prognostic
factor and the outcome. We made an assignment of high risk of bias if any of the following statements applied and we considered there
was a likely high risk of bias as a consequence:
• key adjustment factors were not taken into account in either the design or in the analysis;• key adjustment factors were not measured adequately;• methods or settings for the measurement of adjustment factors were diGerent for diGerent prognostic factor levels or diGerent outcome
levels;• interventions were diGerent for diGerent prognostic factor levels or diGerent outcome levels.
Moderate risk of bias
The observed eGect of the prognostic factor on the outcome may have been distorted by another factor related to the prognostic factor
and the outcome, but there was insuGicient information to make a judgement of low or high risk of bias, or we were uncertain whether the
quality issue was likely to lead to high risk of bias. Alternatively, key adjustment factors considered in the design or analysis were unclear
or the analytical procedure was poorly reported.
Domain 6. Statistical analysis and reporting
The statistical analysis and reporting domain addressed the appropriateness of the study’s statistical analysis and completeness of
reporting. If there were unit of analysis issues, these should have been analysed appropriately.
The analytical approach and the results should have been reported fully, regardless of their findings or level of significance.
Low risk of bias
The reported results were unlikely to be biased, either in relation to the analysis or the reporting of results. We made an assignment of low
risk of bias if all the following requirements were met:
• there was suGicient presentation of data to assess the adequacy of the analysis;• the strategy for model building (i.e. inclusion of variables in the statistical model) was appropriate; in practice, this item was not required
if an adequately designed and reported phase I study was used;• the selected statistical model was adequate for the design of the study (e.g. a confirmatory study was correctly analysed, and unit of
analysis issues were considered appropriately);• there was no selective reporting of results.
High risk of bias
The reported results were very likely to be biased, either related to the analysis or the reporting of results. We made an assignment of high
risk of bias if any of the following statements applied and we considered there was a likely high risk of bias as a consequence:
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• there was insuGicient detail to assess the adequacy of the analysis approach;• the selected statistical model was inadequate;• the analysis approach was inadequate (e.g. in selecting variables for a multivariable analysis or in including mediators in a regression
analysis or ignoring important intervention eGects);• results were reported selectively, either on the basis of the findings or statistical significance.
Moderate risk of bias
The reported results may have been biased, either related to the analysis or the reporting of results, but there was insuGicient information
to decide.
All-domain risk of bias
We defined an all-domain risk of bias for each prognostic factor–outcome combination, taking into account all the above domains, but
especially focusing on selection bias, study attrition, adjustment, and statistical analysis and reporting. As a guide, we assigned risk of bias
as follows: low risk of bias, if all (or all key) domains had low risk of bias; moderate risk of bias, if there was high risk of bias for one key
domain or moderate risk of bias for at least two key domains (with the rest as low risk of bias); or high risk of bias, if there was high risk
of bias for at least two key domains.
Appendix 3. Key prognostic factors and key adjustment factors for venous leg ulcer healing
To assess the reliability of reported associations of biomarkers with healing, we needed to know whether confounding factors were taken
into account in the analyses of the included studies, and this required us to identify key confounding factors. We identified no evidence
on key confounders and did not find reviews of independent prognostic factors for healing VLUs. Therefore, we surveyed the literature for
prognostic factor studies that used multivariable analyses, identified likely key prognostic factors and then investigated whether these
factors were likely to be associated with the biomarkers, thus determining the key confounding factors.
Prognostic factors
We identified 13 cohort studies that examined prognostic factors for venous leg ulcer (VLU) healing at 24 or 52 weeks' follow-up and
reported results of multivariable analyses (Ashby 2014; Barwell 2000; Barwell 2001; Chaby 2013; Gohel 2005; Harrison 2011; Iglesias 2004;
Lantis 2013; Margolis 1999; Margolis 2004; Milic 2009; MoGatt 2010; Scotton 2014). Other than multivariable analysis and the study design,
we did not assess the study quality. The prognostic factors investigated were:
• participant characteristics: age (five studies), gender (six studies), weight/BMI (two studies), ethnicity (one study);• comorbidities: angina (one study), myocardial infarction (one study), hypertension (one study), cerebrovascular accident (one study),
deep vein thrombosis (three studies), diabetes mellitus (two studies), thyroid disease (one study), rheumatoid arthritis (one study);• mobility: mobility (three studies), ankle flexion (three studies), hip/knee replacement surgery (one study);• ulcer characteristics: wound duration (six studies), wound area (seven studies), depth of VLU (one study), grade of VLU (one study),
number of ulcers (two studies), number of previous ulcer episodes (one study), wound covered with fibrin (two studies), wound covered
with eschar (one study), wound debrided surgically (two studies), chronicity (two studies);• limb characteristics: ankle brachial pressure index (one study), lipodermatosclerosis (one study), calf/ankle circumference ratio (one
study), venous ligation/stripping (one study), venous reflux of various types and levels (one study);• Infection (one study), bacterial bioburden (two studies);• other: public assistance/self-pay healthcare (one study);• interventions: two studies.
These results were represented on forest plots to determine trends for prognostic factors with more than two studies or showing dose
eGects (Figure 8; Figure 9; Figure 10; Figure 11; Figure 12; Figure 13). From these results, we identified likely important prognostic factors
and possibly important prognostic factors, by taking into account consistency and dose eGects.
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Figure 8.   Prognostic factors for healing venous leg ulcers: participant characteristics. HR = hazard ratio; OR = odds
ratio
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Figure 9.   Prognostic factors for venous leg ulcer healing: wound characteristics 1. HR = hazard ratio; OR = odds ratio
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Figure 10.   Prognostic factors for VLU healing: wound characteristics 2. HR = hazard ratio; OR = odds ratio
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Figure 11.   Prognostic factors for VLU healing: number of ulcers
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Figure 12.   Prognostic factors for venous leg ulcer healing: mobility and ankle flexion. HR = hazard ratio; OR = odds
ratio
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Figure 13.   Prognostic factors for venous leg ulcer healing: bacteria and infection. HR = hazard ratio; OR = odds ratio;
RR = risk ratio
 • Likely important prognostic factors for healing: smaller wound area (or lower grade or depth of ulcer), shorter duration of ulcer.• Possible important prognostic factors for healing: younger age, smaller number of wounds, ankle flexion (with individual mobility as
a possible surrogate) and lower weight (or BMI).• The evidence from three studies on the prognostic value of bacterial species in wounds appeared to be contradictory and there may
be confounding eGects from treatment (Figure 13) (Lantis 2013; MoGatt 2004; Scotton 2014). However, infection itself was likely to be
a prognostic factor for a lack of healing/delayed healing.
Key adjustment factors
To accurately determine the association between a prognostic factor and the outcome, it was important to adjust for key factors that
distorted that relationship. Key adjustment factors should be statistically associated with both the outcome and the prognostic factor, and
should not lie on a direct pathway between the prognostic factor and the outcome.
We planned to determine key adjustment factors for healing by investigating whether each of the key prognostic factors (KPFs) were
associated (in a univariable analysis) with protease activity, on the basis of the evidence, ensuring that the adjustment factor was unlikely
to be on the direct pathway. If we identified an association of the KPF with protease activity, we termed the KPF a 'key adjustment factor.'
We also discussed possible key adjustment factors with clinicians.
In practice, the evidence was limited. There was some evidence that age could have aGected protease activity and may therefore have been
a key adjustment factor (AshcroO 1997). Additionally, we considered infection likely to be a key adjustment factor, but we were unclear
regarding the KPFs. We tentatively defined two key adjustment factors a priori (age and infection), but recognised that we may have missed
important factors. Therefore, if additional adjustment factors appeared in analyses from several studies, we considered adding these to
the set of key factors and reassessing the risk of bias for all the studies.
We reported and compared any adjusting factors used in the studies, and examined whether there were diGerences between adjusted and
unadjusted analyses.
Appendix 4. GRADE for prognostic factors
Before assessing the GRADE factors for downgrading/upgrading, we assigned an initial GRADE rating as follows (Hayden 2014):
• high for evidence based on phase 2 or phase 3 explanatory/confirmatory studies, i.e. studies aimed at identifying independent
associations between prognostic factor and outcome, or those investigating mechanisms;• moderate for evidence based on phase 1 exploratory studies, i.e. those aimed at investigating all associations, usually in univariable
analyses) or other studies reporting univariable associations or having suGicient data to calculate associations.
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Unlike GRADE for intervention studies, we did not initially rate diGerently the diGerent types of study design (e.g. case-control, retrospective
or prospective cohort studies) because we identified quality issues in the risk of bias assessment.
We took into consideration the following GRADE factors, downgrading (or upgrading) the evidence certainty as follows.
Downgrading the evidence certainty
1. Risk of bias
We assigned serious limitations (downgraded once) when most evidence was from studies with moderate all-domain risk of bias. We
assigned very serious limitations (downgrade twice) when most evidence was from studies with high all-domain risk of bias.
2. Indirectness
Indirectness occurs when any, or all, of the study sample, the prognostic factor and the outcome did not accurately reflect the review
question for most of the evidence. We downgraded the evidence certainty accordingly, taking into consideration whether diGerences were
likely to be selection bias or indirectness.
If the evidence was based on RCT data analysed as an observational study, we considered whether the trial's inclusion criteria made the
evidence indirect (Iorio 2015).
3. Inconsistency
The GRADE criteria for judging inconsistency included variability in point estimates, extent of overlap in confidence intervals (CI), and
considering where point estimates lay in relation to decision thresholds. Prognostic studies were oOen large and so CIs were narrow; this
could have meant the overlap was small, leading to large I2 statistic values, which could have been misleading (Iorio 2015). We will not
rely solely on statistical measures of inconsistency, but took these into account alongside assessing variations in eGect estimates across
studies, considering whether the point estimates lay on either side of the line of no eGect, or whether the range of point estimates were
consistent with more than one conclusion. We conducted prespecified subgroup analyses if there were suGicient studies before making
a judgement on inconsistency (Guyatt 2011b).
4. Imprecision
The evidence was considered to be imprecise if we found the following:
• for meta-analysis only:* there was an insuGicient sample size;* an imprecise estimate of the eGect size in the meta-analysis: i.e. the CI was wide and overlapped the null and contained values
implying that the factor played an important role in protecting or putting the individual at risk;* there was within-study imprecision: for the majority of the studies, sample size justification was not provided and there were fewer
than 10 outcome events for each prognostic variable (for dichotomous outcomes) or there were fewer than 100 cases per regression
analysis (Hayden 2014), or as few as two participants per prognostic variable (Austin 2015) (for continuous outcomes);* we considered whether any CIs were wide because of inconsistency, which could have led to double counting of GRADE factors (Iorio
2015).• for a narrative summary:* within-study imprecision: sample size justification was not provided and there were fewer than 10 outcome events for each
prognostic variable (for dichotomous outcomes) or there were fewer than 100 cases per regression or two participants per prognostic
factor (for continuous outcomes);* imprecision in the estimation of the eGect size within each primary study, and across-study imprecision: there were few studies and
a small number of participants across studies.
5. Publication bias
We examined funnel plots for asymmetry provided there were at least 10 studies. We also considered downgrading routinely, unless the
value of the risk/protective factor in predicting the outcome had been repetitively investigated, ideally by phase 2 and 3 studies.
Upgrading the evidence certainty
6. Large e+ect estimate
We considered upgrading the evidence certainty if the pooled eGect (for meta-analysis) was moderate or large, or if a moderate or large
similar eGect was reported by most studies (for a narrative summary). An eGect estimate was considered moderate if the odds ratio was ≥
1.5 or ≤ 2, and large if it was > 2 (Hemingway 1999). We noted that risk of bias may have led to inflated eGect estimates.
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7. Dose e+ect
We upgraded the evidence certainty if, for meta-analysis, a gradient was present between analyses for factors measured at diGerent levels
(doses). For a narrative review, we considered upgrading if studies seemed similar apart from dose.
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